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ABSTRACT 
 
A QUANTITATIVE STUDY OF DRUG RECRYSTALLIZATION IN DRUG-IN-ADHESIVE 
(DIA) TRANSDERMAL PATCHES USING VIBRATIONAL SPECTROSCOPY 
 
 
 
By 
Yi Li 
May 2019 
 
Dissertation supervised by Carl A. Anderson, Ph.D. 
Drug-in-adhesive (DIA) transdermal patches are an important type of transdermal drug 
delivery system (TDDS). The drugs used in the DIA system are frequently present in metastable 
forms, such as amorphous solids or supercooled liquids. These drug states are thermodynamically 
unstable and tend to undergo phase changes, such as recrystallization, throughout the lifetime of 
transdermal products.  Recrystallization of the active pharmaceutical ingredient (API) can 
adversely affect the efficacy (slowdowns of drug release due to low solubility) of transdermal 
products. The role that the extent of crystallization plays in determining the physiochemical 
properties and release behavior of DIA patches has not been fully investigated. There are no widely 
accepted methods for determining crystalline content of API(s) in DIA systems.  The DIA patches 
have distinct mechanical and optical properties that render the existing solid-state phase 
quantification approaches insufficient. Calibration standards for phase quantification are typically 
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prepared by thoroughly mixing crystalline API powders with the amorphous API created in solid 
dispersions. The tackiness of the adhesive polymers prevents the blending and mixing of the 
crystalline and amorphous API. Moreover, the detection limit of the conventional reference 
method, X-ray diffraction (XRD), is higher for a semi-solid thin film than for a solid mixture. This 
dissertation introduces a systematic approach to quantify the crystalline content of the API in DIA 
systems. This approach uses a novel method of preparing calibration standards and a spectroscopic 
method to reliably predict crystalline content in DIA patches.  
Understanding the variability of the sample system is vital to developing an analytical 
method. Calibration samples must have the variability of the target samples for which the method 
is designed. The DIA calibration samples were prepared by spiking patches with crystalline drug 
to mimic the crystalline distributions in authentically recrystallized patches. The physical stability 
of the spiked crystals was determined by tracking the size of crystals using microscopic imaging. 
The uniformity of the spiked crystal was determined at the scale or size at which the spectroscopic 
tools were used to examine the authentically recrystallized samples.  
Spectroscopic tools, including Raman spectroscopy and near-infrared spectroscopy (NIRS), 
can be used to determine the crystallinity of drug in transdermal patches rapidly and non-
destructively with a limit of detection comparable to that of the conventional solid-state 
characterization techniques. Analytical sensitivity, selectivity, and depth of penetration were 
determined for the DIA system using the spectroscopic systems. Comparisons between the 
sensitivity of the developed spectroscopic methods and an XRD method were acquired to 
determine the sensitivity of the techniques at low levels of crystallinity.  
Spectral data collected on calibration samples via NIRS and Raman were related to the 
crystalline content according to a design of experiment that minimized the correlation between the 
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crystalline and the solvated API. The spectral features and diagnostic measures of two independent 
test sets were compared to demonstrate the validity of the calibration samples. One test set was 
made by spiking crystalline API and the other was made by recrystallization. The suitability of the 
spectroscopic methods was validated using the fit-for-purpose concept. Sample specific 
multivariate detection limit (MDL) was calculated. It accounts for variance associated with all 
possible steps involved in the method development and model testing. An accuracy profile derived 
from bias and intermediate precision related the method performance to the predefined acceptance 
criteria.  
Development of reliable solid-state quantification methods is a critical component in 
understanding crystallization processes. In this work, the effect of environmental variability on the 
physical stability of the DIA patches was evaluated using changing temperature and humidity 
conditions. The recrystallization profile determined from the Raman method was fit to a Weibull 
function to generate the recrystallization rate constants. The impacts of temperature and humidity 
on crystallization rates were used to determine the roles that thermodynamic and kinetic driving 
forces play in determining the physical stability.  
In summary, sample representativeness, analytical capability, and method suitability were 
integrated to form a systematic approach for crystallization quantification. The results of this work 
demonstrated that a reliable crystalline content quantification method can be developed using NIR 
spectroscopy and Raman spectroscopy for DIA transdermal patch delivery systems. The 
quantitative spectroscopic methods are potential tools for supporting formulation development and 
physical stability evaluation of transdermal products in the pharmaceutical industry. 
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Chapter 1 : Introduction 
1.1 Statement of the Problem 
Transdermal patches represent a convenient alternative to oral delivery.1 They are placed 
on the skin to deliver drugs percutaneously into the bloodstream. The benefits of transdermal 
patches include minimization of first-pass effects, avoidance of gastrointestinal irritation and 
reduced frequency of dosage.2-3 Drug-in-adhesive (DIA) and drug-in-reservoir patches are the two 
main designs of passive transdermal drug delivery systems.3-4 DIA patches are more frequently 
manufactured than reservoir-type patches because of their simple and flexible design, which is 
well suited for mass production. A DIA patch typically contains a liner, a backing, an adhesive 
and a drug. Delivery of drugs through the skin is challenging because of the excellent barrier 
properties of the stratum corneum.5 Improved permeation and release profiles are reported for DIA 
systems that contain maximized drug concentrations.6 The increase in the delivery of drug across 
the skin increases proportionally with the degree of supersaturation of the drug in the polymer.7 
The system becomes supersaturated when the degree of supersaturation is above the solubility of 
drug in the polymer. Supersaturation can be achieved by combining the drug and the adhesive into 
a solid dispersion via melt-quenching or solvent casting. However, drugs formed through these 
manufacturing routes either become amorphous solids or supercooled liquids that readily 
crystallize over the shelf-life of transdermal products.  
The instability of solid-state drugs is one of the most critical problems found in transdermal 
patches.8 Crystallization of drugs in supersaturated transdermal patches has significant impacts on 
patch release. When the amorphous drug recrystallizes from its supersaturated solution, any solute 
removed from the solution is replenished by the solid phase via dissolution into the solvent. 
However, the crystallized drug is far less likely to re-dissolve into the solid matrix. The 
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recrystallized drug remains sequestered in the crystalline phase and cannot be delivered; whereas 
the drug is delivered from the polymer where the concentration of the drug goes down. Therefore, 
a lower amount of free drug molecules remain available for absorption as a result of 
crystallization.9  The drug must remain dissolved in its amorphous state (or solvated state) to 
achieve rapid release from the transdermal patch. Crystallization in most transdermal patches is 
incomplete, meaning that after some time there will be coexisting crystalline and dissolved drug. 
As a result, significant batch-to-batch variation of the release and physiochemical properties may 
occur. Meanwhile, patches with increased crystalline content are more likely to undergo hazing, 
cracking and even sliding from the skin.10 Furthermore, the adhesive properties of DIA patches, 
such as viscoelasticity and tack, may also be adversely affected.11 In addition, factors which affect 
the kinetics of recrystallization, such as temperature and humidity, can further reduce the physical 
stability of DIA patches and lead to drug crystallization during storage. Crystal formation testing 
is mandatory for new transdermal drug product applications. The patch stability study must be 
conducted over at least six months under varying environmental conditions to study the effect of 
temperature and humidity on the physical stability of patches. Therefore, the changes in 
transdermal performance due to the solid-state instability not only pose risks to the patients but 
also exacerbate the formulation and regulatory burdens.  
Reliable analytical techniques are required for stability monitoring of transdermal patches 
throughout their shelf-life. The degree of crystallinity of drugs can be used as a critical quality 
attribute (CQA) for non-crystalline DIA formulation development and stability studies. 
Characterizing the solid-state kinetics of the recrystallization process of amorphous drugs in DIA 
patches allows establishment of mathematical relationships between physical stability and factors 
(formulation and process) that give more insight into transformation mechanisms.12 
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Recrystallization kinetics cannot be accomplished without an analytical method that enables the 
fast and reliable determination of crystalline content. Traditional solid-state quantification 
techniques have many problems. The quantification of solid phases via differential scanning 
calorimetry (DSC) requires optimization of parameters (heating rate and heating cycle) and 
minimizing the influence of the thermal history of samples. The technique also suffers from the 
problem of sub-sampling. The capabilities of both methods for quantifying crystalline drug in DIA 
system is adversely influenced by their limit of detection (LOD).    
The use of spectroscopic tools may alleviate the above-mentioned problems. Raman 
spectroscopy and near-infrared spectroscopy (NIRS) have the potential to non-destructively and 
rapidly determine the crystallinity of drugs in DIA transdermal patches without sample preparation. 
Differentiation of amorphous and crystalline phases by molecular spectroscopic techniques relies 
on the absorption and scattering of light at particular wavelengths that reflect molecular vibrations 
and interactions among functional groups.13 The spectral differences between amorphous and 
crystalline materials are caused by the presence or absence of spatial order and long-range 
translation symmetry.14 Both NIR and Raman have demonstrated good sensitivity and selectivity 
to crystalline phases in the presence of amorphous materials.15 Quantification of low 
concentrations (<2%) of crystalline drug for pharmaceutical tablets has been achieved 
previously.16-18 However, the suitability of Raman and NIRS to determine crystalline drug content 
in transdermal patches has not been demonstrated.   
There are no validated approaches for determining crystalline drug content in DIA systems. 
The European Medicines Agency (EMA) recommends using microscopic and photometric counts 
as quantitative measures of crystallization in transdermal products.19 Compared to the typical solid 
dosage forms of tablets and powders, DIA patches present distinct mechanical and optical 
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properties that render the existing solid-state phase quantification approaches insufficient. The 
general procedure of developing a quantitative spectroscopic method for crystallinity 
determination includes calibration design, preparation of calibration samples, sample 
measurements, reference analysis, and multivariate regression analysis. Preparing calibration 
samples to reach the desired levels of crystallinity is challenging. Calibration samples for phase 
quantification are usually prepared by thoroughly mixing separately prepared crystalline and 
amorphous phases into a homogeneous blend.20 The strong tackiness of the adhesive polymers 
prevent the blending and mixing of the DIA components. Even if mixing the drug with the adhesive 
is feasible, the energy imparted during the mixing procedures potentially induces polymorphic 
transformation and changes in crystallinity. As a result, the assumed crystallinity may no longer 
be accurate. Alternatively, NIR chemical imaging and Raman mapping can provide spatial 
information of the amorphous and crystalline components at the surface of transdermal patches 
without the need to make calibration samples.21-22 However, determining crystallinity via 
classifying and counting pixels assigned to crystalline and amorphous components is considered 
semi-quantitative at best. The quantitative capabilities of these methods are still under debate.  
Physical instability is the major hurdle that limits the commercial development of 
transdermal patches.23 Controlling the critical factors that led to crystallization is a significant 
challenge faced by developers. The degree of crystallinity can be used to relate material 
characteristics and process parameters to the physical stability of amorphous drugs in transdermal 
patches. For example, the effect of small changes in the polymer molecular weight, solvent type, 
mixing, drying, or other factors on the drug recrystallization can be ranked according to drug 
crystallinity. However, no procedure for quantification of crystalline drug in DIA transdermal 
patches has been reported. The work outlined in this dissertation demonstrates how fast, non-
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destructive spectroscopic methods can be used to accurately determine crystallinity of drug in DIA 
transdermal patches.  A systematic approach that considers all relevant aspects of the analytical 
method (sample system, analytical system and quantitative model) represents a unique opportunity 
to investigate and control factors governing the recrystallization of drug in transdermal patches. 
 
1.2 Hypothesis and Objectives 
This dissertation is based on the central hypothesis that the extent of crystallization in 
transdermal patches can be quantitatively determined by Raman spectroscopy and Near Infrared 
spectroscopy. Thus, the quantitative methods for the determination of crystallinity of drug can be 
used in transdermal formulation development and studies of recrystallization kinetics.  
Given the central hypothesis, the objectives of this dissertation were to:  
1. Determine the feasibility of using NIR spectroscopy and Raman spectroscopy to determine 
crystallization of ibuprofen in Duro-Tak® 2052 
- Characterize drug-in-adhesive patches to determine the influence of patch 
physiochemical properties on NIR and Raman signal 
- Determine instrumental sensitivity and selectivity to two physical forms of drug 
(crystalline and supercooled)  
2. Develop a powder coating-based method to prepare patches with known drug crystallinity 
- Verify the physicochemical properties of the spiked samples meet the requirements 
(physical stability and coating uniformity) to be used as calibration samples  
3. Develop a quantitative calibration using NIR and Raman spectra for accurate crystalline 
content determination in DIA patches 
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- Calculate multivariate detection limit based on a total error approach 
- Demonstrate method capability in predicting crystalline content in both spiked and 
naturally recrystallized patches  
- Demonstrate a strategy for validation using accuracy profile and validation criteria 
(specificity, accuracy, precision and robustness).  
4. Evaluate physical stability of supersaturated DIA patches via the established quantitative 
methods 
- Determine crystallization kinetics of the active pharmaceutical ingredient (API) in DIA 
patches using Raman spectroscopy 
- Quantify the effects of changing temperature and humidity on drug crystallization 
The following flow chart demonstrates the topics covered in this document:   
	
Figure	1.1	Summary	of	work	presented	in	this	dissertation. 
Figure 1.1 demonstrates a systematic approach for drug crystalline content determination in DIA 
patches, covering all aspects of the analytical method including sample preparation and 
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characterization, analytical feasibility assessments, and multivariate model development and 
validation. This platform can be used for physical stability evaluation of DIA patches. It also offers 
a means to study the effects of formulation factors and storage conditions on crystallization in DIA 
patches.  
 
1.3 Literature Survey 
1.3.1 Drug-in-adhesive Transdermal Patches 
A transdermal patch is a flexible, multi-layered, pharmaceutical, single dose preparation of 
varying size containing one or more active pharmaceutical ingredients (APIs) to be applied to 
intact skin for systemic absorption.24  The transdermal drug delivery provides a prolonged release 
for drugs of short biological half-life, avoiding the first-pass effect and allowing removal of the 
patch conveniently during transdermal administration.25  
Transdermal drug delivery can be achieved via active or passive systems. Active systems 
rely on external energy such as heat, electric current, sound waves or transient high-voltage 
electrical pulses to achieve the transport of the drug through the skin; passive delivery systems rely 
on chemical potential (concentration gradient). Drug diffusion through the skin into the systemic 
circulation is driven by the concentration gradient of the drug across the skin and the difference in 
solubility between the adhesive and skin. Patches for passive drug delivery can be classified into 
three main types: drug-in-adhesive (DIA) systems, polymer matrix systems and drug-in-reservoir 
systems.  
The drug-in-adhesive system are the simplest form of passive transdermal drug delivery 
systems with reference to the straightforward design, uncomplicated manufacturing process, and 
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ease of application.26 The adhesive polymer fulfills a dual function in DIA systems. One function 
is providing adhesion and the other is controlling drug release.  A drug is directly dispersed into 
the adhesive polymer via solvent casting or hot melt extrusion. The DIA layer is then supported 
by an impermeable backing film on one side and is laminated with a removable release liner on 
the other side. The DIA patch is featured by the lighter, thinner and more flexible design that 
improve the conformity with skin surface variations.4, 27 The simple design of the DIA system is 
favorable with respect to manufacturing, quality control and continuous product improvement.26  
Due to these reasons, the DIA type products have accounted for the largest share of the TDDS 
market since 2002.4  
 
1.3.1.1 Pressure Sensitive Adhesives 
Adhesives are a critical component of DIA systems. They are used to maintain close 
contact between the patch and the skin surface. Among the different classes of adhesives, pressure-
sensitive adhesives (PSAs) are preferred. A pressure sensitive adhesives adheres to a substrate with 
light pressure and leaves insignificant amounts of  residual adhesive upon removal from skin.28  
A pressure-sensitive adhesive must meet several requirements to be an effective component 
of DIA patches. The adhesives must provide mechanical functions and release properties. 
Mechanical functions of the PSAs include skin adhesion, peel adhesion and resistance to shear. In 
terms of drug release, the PSAs govern the partitioning of drug into the skin from the DIA system. 
Meanwhile, long-term chemical compatibility between the adhesive, the drug, and any excipients 
is a pre-requisite for the PSAs used in DIA systems.  
Among different types of PSAs, three of them are commonly used in transdermal patches. 
They are polyisobutylenes (PIBs), polysiloxanes (silicones) and polyacrylate copolymers 
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(acrylics). The selection of a PSA to be used in a TDDS is based on factors such as patch design, 
intended wear time, wear conditions and processability.28 Acrylic PSA was selected for this study 
for its good chemical stability and inherent adhesion properties compared with PIBs and 
polysiloxane PSAs. In addition, acrylic PSAs provide better solubility and permeability for many 
drugs.28  
This section will only discuss the structure and key properties of acrylate PSAs: chemical 
compatibility and adhesive properties. These topics are most relevant to the techniques that this 
dissertation covers.  
Acrylic PSAs are formed by copolymerization of acrylic ester, acrylic acid and other 
functional monomers which may contain -OH or -COOH groups. The PSA acrylic monomers used 
in polymerization are comprised of 50-90% of primary monomers, 10-40% of modifying 
monomers, and 2-20% of monomers with functional groups.29 Only four acrylic esters have been 
commonly used as primary monomers. They are 2-ethylhexyl, butyl, ethyl and iso-octyl acrylate.30 
The modifying monomers typically contain methyl acrylate, methyl methacrylate, vinyl acetate 
and styrene. Functional groups often added to the monomers include carboxylic, hydroxyl, epoxy, 
amide and organo-silane.31 
Acrylic PSAs are highly resistant to oxidation because they only contain saturated 
hydrocarbon bonds that are hard to break. Stabilizers are frequently added to silicone-type 
adhesives to inhibit oxidation of the polymer arising from degenerative effects of oxygen, light, 
heat, and high temperature.32 Examples of stabilizers are antioxidants and UV absorbers. 
Antioxidants scavenge free radicals and UV absorbers retard the photolysis of certain types of 
adhesive polymers.  The need to add a stabilizer, which has the potential to cause skin irritation, 
is reduced because acrylic PSAs are chemically stable.   
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Types of monomers, cross-linking of functional groups and molecular weight are the three 
key parameters governing the adhesive properties of acrylic PSAs. The flexibility and tackiness of 
the adhesive is dependent on the side-chain length of the primary monomers.30 The primary 
monomeric component has a low Tg that ensures a soft, tacky film. Therefore, plasticizer or 
tackifiers are not required in PSA systems. However, primary monomers lack the balance between 
tackiness and cohesive strength needed to resist an applied shear stress, other components are 
required to make a useful PSA.32 A modifying monomer provides a clean removal and resistance 
to cold flow while a functional monomer is frequently used to improve the solubility or 
permeability of the acrylic polymers.  
 
1.3.1.2 Skin Structure and Drug Selections 
Skin is the most accessible surface for drug delivery. However, it remains a significant 
barrier to the penetration of drugs. The outmost layer, stratum corneum, is approximately 15 to 20 
µm thick. It is composed of non-living corneocyte cells and intercellular lipids. Underneath this 
layer is the viable epidermis, which measures 130-180 µm.33 The inner layer of the skin is the 2-3 
mm dermis, which contains nerves, sweat glands, sebaceous glands, hair follicles, and abundant 
capillaries for systemic drug distribution.34-35 The process of transdermal drug uptake through the 
skin is governed by passive diffusion into the stratum corneum. The corneocytes are embedded in 
intercellular lipids, forming a “brick-and-mortar” structure.36 Drug molecules diffuse through the 
intercellular lipids via paths winding around corneocytes. The hydrophilic molecules travel 
through the lipid head group regions and lipophilic molecules travel through the lipid tails.34 
Drugs suitable for transdermal delivery must possess suitable physiochemical properties, 
including an aqueous solubility over 1.0 g mL-1, a log P between 1.0 and 2.0, a molecular weight 
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under 400 Da, and a melting point below 200 °C.37 A balance between lipophilicity and 
hydrophilicity is needed to cross the lipophilic stratum corneum and cause absorption into the 
systemic circulation.25  Additionally, drugs must not be locally sensitizing or irritating. Because 
of these criteria, only a limited number of drugs are suitable to transdermal administration. 
 
1.3.1.3 Liner and Backing  
A release liner is a thin layer that protects the drug layer until use. It is peeled from the 
adhesive layer prior to use. Low surface energy coatings are applied on one or both sides of the 
release liner to facilitate detachment. The coating materials include polyfluorosilicone, 
polysilicone and polyperfluorocarbons.28  
Depending on the design and target use of a transdermal patch, backing materials are either 
permeable or occlusive. Occlusive backings are composed of synthetic polyesters that can cause 
hydration of the stratum corneum and thereby promote the permeation of drugs.38-39 However, skin 
occlusion may cause hydration dermatitis when patches are applied for an extended period.40 
Permeable, or nonocclusive backings are composed of fiber-based materials that are preferred for 
patient comfort over long patch wear duration.   
 
1.3.1.4 Supersaturation and Permeation Enhancement 
The diffusion process can be approximated by Fick’s first law of diffusion:41-42 
' = )*+ ,-.,/0 	  (1.1) 
where J is the flux (g/s), S is the cross-sectional area(cm2), D is diffusion coefficient of drug 
molecules in the skin (cm2/s), K is stratum corneum-matrix partition coefficient, 23 and 24 are 
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concentration of drug in the transdermal patch and in the skin(g/cm3) respectively, and h is the 
length of the diffusional pathway(cm). If sink conditions hold in the accepting compartment (skin), 
that is 24 ≈ 0,  
' = )*+ ,-0   (1.2) 
Higuchi postulated that:43 
+ =	 7/7- = 7/∗7-∗  (1.3) 
where  94∗  and 93∗ are the saturated concentrations in the skin and the transdermal patch. 
Substitution of Equation (1.3) in to Equation (1.2) leads to: 
' = )*+ ,-0 = )* 7/∗,-7-∗0  = )* ,-7/∗7-∗0 = :47/∗0   (1.4) 
where ; denotes the thermodynamic activity that equals to ,-7-∗ . Equation (1.4) clearly shows that 
the permeation rate increases with the drug’s activity. Different mathematical equations describing 
diffusion-controlled systems can be found in the literature depending on whether the initial drug 
concentration is below or above drug solubility in the adhesive matrix. 
If the drug is molecularly dispersed in the adhesive, i.e. the initial drug concentration is 
below the solubility in the adhesive matrix, the system is called a monolithic solution.44 The drug 
release from monolithic solution systems can be described by:45  
<=<> = 1 − ?@A BCD	[.	F AGHI AJA=KA ](N@OP)AR@ST   (1.5) 
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where  UV	;"W	UR denote the cumulative amounts of drug released at time t and at infinite time, 
respectively, D is the diffusion coefficient of the drug within the system, and l represents the total 
thickness of the film.  
When the drug is homogeneously distributed within an adhesive at an initial concentration 
that exceeds drug solubility,44and the system has reached equilibrium via drug crystallization,. this 
system is called a monolithic dispersion and the drug release from such a patch follows Higuchi’s 
equation:46 
UV = X )2Y 22[@[ − 2Y \  (1.6) 
where  UV denotes the cumulative amounts of drug released at time t, D is the diffusion coefficient 
of the drug within the system, A is the total surface area of the film exposed to the release medium, 
and 2[@[  and 	2Y  represent the initial drug concentration and drug solubility in the system, 
respectively.  
In equilibrated suspension systems, the steady state flux of formulations with different 
initial concentration should be very similar if the dissolved drug concentration remains close to 
drug solubility.  However, according to Equation (1.4), the rate of diffusion in a non-equilibrated 
system changes with thermodynamic activity (,-7-∗), or the degree of supersaturation. Transdermal 
systems are often formulated with the drug supersaturated in the adhesive to achieve maximum 
thermodynamic driving force for passive diffusion across the skin.  
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1.3.1.5 Manufacturing Processes 
DIA patches can either be manufactured using the solvent casting or the hot-melt technique. 
The solvent casting technique involves dissolving the API, the adhesive, and excipients in a 
common, volatile solvent.  The homogenized solution is coated onto a release liner or a backing 
film. The film is dried in to remove the solvent.  In the hot-melt technique, the API is added to the 
adhesive and heated to a temperature that allows the API to be completely melted and uniformly 
dispersed.47 The hot-melt mixture is then extruded and laminated with a release liner and a backing 
under moderate pressure.  
Amorphous API can be formed, either intentionally or unintentionally, during either patch 
manufacturing process. Heat and mechanical energy from the manufacturing may transform the 
crystalline drug into a metastable state(s). A few additional techniques have been used to produce 
drug in amorphous films. An inkjet printer was used to deposit a drug solution onto a polymer 
substrate to attain personalized dosage forms.48 The method has demonstrated ability to print drug 
solutions on any porous or non-porous substrates and biodegradable films.49 Solid-dispersion 
extrusion is a variant of hot-melt technique. Instead of mixing the powered drug with the molten 
polymer, a drug is dissolved in a solvent and added to the melt. In this way, material mixing can 
be performed at a lower temperature to prevent chemical degradation. Another method for making 
amorphous transdermal patches is electrospinning. A high voltage electric filed is applied to 
polymeric fluid stream to form solid fibers.50 The electrospun fibers are then compressed into films. 
A list of manufacturing techniques is listed in Table. 1.1. 
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Table 1.1 Transdermal films manufacturing methods 
Preparation method Drug Dose Use Film thickness Reference 
Ink-jet printing Clonidine 7.6 - 250 µg/strip Oral 0.1 ± 0.01mm 51 
Ink-jet printing Theophylline 7.49 ± 0.13 µg/cm
-2 per pass 
of printing NA NA 
52 
Drop printing Naproxan 30 and 70 (%, w/w) NA 60 - 90 µm 53 
Flexographic printing Tadalafil & rasagiline mesylate 0.24 - 1.10 mg/6 cm
2 Oral 54.7± 0.5 µm & 56.8 ± 0.8 µm 
54 
Solvent casting betamethasone 17-valerate 1.0 (%, w/w) 
Prolonged 
dermal delivery 0.2 ± 0.02 mm 
55 
Solvent casting Itraconazole 40 (%, w/w) NA 0.15 ± 0.01 mm 56 
Electrospun Peptide P12 0.6 and 6 (%, w/w) 
Topical fiber 
mats for skin 
burns 
0.2 mm 57 
Electrospun 
 Caffeine 11 (%, w/w) NA NA 
58 
Solvent casting Betamethasone 17-valerate 1.2(%, w/w) Topical 10 µm 
59 
Solvent casting 4-ethynyl-2-fluoro-2-deoxyadenosine 0.1 (%, w/w) Topical vaginal 97 ±7.5 µm 
60 
Coating film Nicotine 2.41 - 2.63 mg/6.51 cm2 Oral NA 61 
Spin-coating Felodipine 50 (%, w/w) NA 5 - 10 µm 62 
Continuous tape 
casting 
Fenofibrate & 
Naproxen 
FNB 4.7 - 26.0 
NPX 2.8 – 23 (%, w/w) Oral 
500 – 1000 µm 
(wet thickness) 
60 
Hot-melt extrusion with 
flex-lip film die 
Clotrimazole 
& nystatin 10 (%, w/w) 
Antifungal 
denture 
adhesives 
0.34 ± 0.02 mm 63 
Hot-melt extrusion –
injection molding Felodipine 10, 20, and 30 (%, w/w) Buccal patches 
NA 
 
64 
	16 
	
1.3.2 Drug Crystallization in DIA Systems 
The crystalline drug must dissolve into the polymer to permeate into skin. An effective 
way to improve drug delivery is to use amorphous solid dispersion (ASD).65 The drug in an 
amorphous solid dispersion is preferably in the molecularly dispersed state.66 Transdermal systems 
are frequently formulated with the drug supersaturated in the adhesive to achieve maximum 
thermodynamic driving force. However, recrystallization is spontaneous with the high internal 
energy. Different approaches for explaining the drug crystallization in polymer matrix have been 
postulated, but most of the methods only apply to systems where the storage temperature is lower 
than the glass transition temperature (Tg) of the drug-polymer system. Although the drug-in-
adhesive systems do not fall into this category (Tg <0 °C), an overview of the current views on 
factors contributing to the crystallization in solid state would still be of great value to the 
understanding and minimization of the unwanted drug crystallization in transdermal patches. 
Crystallization from supersaturated solid systems is a multi-step process that include 
amorphous phase separation, nucleation and crystal growth. Amorphous phase separation and 
nucleation usually precede crystal growth; however, in most cases, the three events are concurrent.   
 
1.3.2.1 Amorphous Solid Dispersion 
A solid dispersion is defined as a formulation where one (or more) active ingredient(s) 
is(are) dispersed in an inert carrier or matrix.67-68 A solid dispersion in which drug and carrier are 
both amorphous is termed amorphous solid dispersion (ASD). An ASD can be classified as either 
a molecularly dispersed system or a phase-separated system depending on the number of 
amorphous phases. In amorphous molecular dispersions the drug(s) and the polymer(s) are mixed 
at the molecular level;69-71 whereas in phases-separated ASDs drug(s) and polymer(s) develop 
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separate sub domains. Figure 1.2 demonstrates the structures of these two sub categories. 
Molecularly dispersed ASDs are reported to have many preferred properties over phase-separated 
ASDs. They have greater dissolution rates than the phase-separated systems for a number of poorly 
soluble drugs72-73. The physical stability is improved significantly by bringing drug and polymer 
molecules to the closest proximity in molecularly dispersed ASDs in which there are strong inter 
molecular interactions i.e. ionic, H-bond and electrostatic forces.74-78 
 
Figure 1.2 Schematic demonstration of two types of amorphous solid dispersions 
 
1.3.2.2 Amorphous Phase Separation 
Prior to phase separation, a drug is molecularly dispersed in an amorphous polymer matrix. 
If the drug concentration is lower than the equilibrium solubility of drug in polymer, the system is 
thermodynamically stable. However, the equilibrium solubility of drug in polymers may be 
relatively low at pharmaceutically relevant temperatures. Most molecularly dispersed amorphous 
solid dispersions become supersaturated as temperature is decreased from processing to storage. 
This can result in amorphous drug aggregates and potentially crystallization of drug. Compared to 
drug crystallization, a lower energy barrier is required to form a metastable structure of amorphous 
drug aggregates.66  
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1.3.2.3 Nucleation 
Nucleation can be classified as either primary or secondary processes. Primary nucleation 
happens in a system that does not contain any nuclei, while secondary nucleation refers to 
nucleation occurring in the vicinity of preexisting crystals.79 Primary nucleation may occur 
spontaneously (homogeneous) or can be induced by the foreign surfaces (heterogeneous). The 
overall kinetics of nucleation follow:79 
! = # exp − ∆)*+   (1.7) 
where J is the rate of nucleation, i.e. the number of nuclei formed per unit time per unit volume, ∆, is the overall excess free energy between a small solid particle of solute and the solute in 
solution, k is the Boltzmann constant, A is the pre-exponential factor and T is temperature in Kelvin. ∆, is equal to the sum of the surface excess free energy, ∆,-, i.e. the excess free energy between 
the surface of the particle and the bulk of the particle, and the volume excess free energy, ∆,., i.e. 
the excess free energy between a very large particle and the solute in solution.79  
∆, = ∆,- + ∆,. (1.8) 
where∆,-  is a positive quantity and is proportional to interfacial tension (0 ) between the 
developing crystalline surface and the supersaturated solution in which it is located.  ∆,.  is a 
negative quantity proportional to 12.   
∆,- = 44150 + 62 412∆,7 (1.9) 
The maximum value of  ∆, corresponds to the critical nucleus, 18 is: 
∆,89:; = <=>?@2(∆)B)D  (1.10) 
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where ∆,7  is the free energy change of the transformation per unit volume. The ∆,7  can be 
estimated from the basic Gibbs-Thomson relationship for a non-electrolyte:  
∆,7 = − 5?9 = *+ EF -7   (1.11) 
where S is the degree of supersaturation (c/c*) and v is the molecular volume. The rate of 
nucleation can be derived from Equation (1.10), Equation (1.11): 
! = #GH IJKL@BD@M@N@ OPQ D (1.12) 
Several variables that are important for the rate of nucleation are temperature, degree of 
supersaturation, and interfacial energy. In a study that evaluated the impact of interfacial energy 
on the crystallization tendencies in a series of Pentitols ( xylitol, adonitol, 1-arabitol and d-arabitol), 
the crystallization processes of the pentitols were dominated by the interfacial energy rather than 
by a competition between the thermodynamic driving force and the molecular mobility.80 However, 
since the liquid-crystal surface energy is difficult to determine independently, its relative intensity 
were reflected by the compound specific molecular conformations.  
Other thermodynamic properties such as configurational entropy (Sc) and entropy of fusion 
(ΔSm) have been measured and correlated to the crystallization tendency. The configurational 
entropy for a material can be expressed as: 
R8STU V = 	∆RX − YZ,\]^_++`+ aV  (1.13) 
where Cp,conf is configurational heat capacity, the difference in the heat capacity between the 
amorphous and crystalline states. Zhou relates Sc, and molecular mobility of five structurally 
diverse amorphous compounds to their crystallization behavior. Compounds with the highest Sc 
and lowest mobility were the most difficult to crystalize.81 The molecules with higher 
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configurational entropies have more configurations thus it takes longer for the compounds to find 
the proper orientation to nucleate.82 
 
1.3.2.4 Crystal Growth 
Nucleation and crystal growth are two separate but concurrent processes. Molecules 
continue to transfer from the undercooled liquid to the surface of the nuclei during crystal growth. 
The mathematical equation proposed by Jackson to explain the dependence of growth rate b on 
thermodynamic and kinetic factors is:83-84 
b = =cdeD f exp − g-* [1 − exp − g)*+ ]  (1.14) 
where a is the molecular diameter, D is the diffusion coefficient, k	is the diffusion jump distance, 
f is the fraction of interface sites that are active growth sites, ΔR and Δ, are the entropy and the 
free energy difference between the crystalline and the supercooled liquid, k is the Boltzmann’s 
constant, and T is the temperature. Equation (1.14) describes an opposite temperature dependence 
of the molecular mobility (diffusion coefficient) and thermodynamic driving forces (ΔR	and Δ,). 
A maximum crystallization rate often shows up between Tm and Tg. The crystal growth rate is 
small at both high and low temperatures because molecular mobility is small below Tg and 
thermodynamic driving force is small as temperature approaches Tm.  
The molecular mobility has a strong effect on the rate of crystallization. An effective 
strategy to slow down drug crystallization is to make amorphous solid dispersions. In these solid 
dispersions, a polymer with high viscosity is used to trap the molecules thus sustaining the 
supersaturation of drug for an extended period. Glass transition temperature (Tg) has been used to 
indicate molecular mobility. The difference between storage temperature and the Tg is frequently 
	21 
	
used as an approximate measure of physical stability of an amorphous solid dispersion.82 The Tg 
of the PSAs are usually much lower than the storage temperature, allowing the DIA system to be 
elastic but prone to drug recrystallization.   
Among the many factors that influence molecular mobility, temperature and humidity have 
been shown to have practical influence on the physical stability of drug in transdermal systems.  
 
1.3.2.5 Effect of Temperature on Crystallization 
Both nucleation and crystal growth are temperature dependent. However, the influence 
temperature has on nucleation is different from that on crystal growth. That is because the driving 
force for crystallization has complex dependence on molecular mobility and on thermodynamic 
parameters. The relationship between temperature and nucleation, crystal growth and overall 
crystallization rates is illustrated in Figure 1.3.   
 
Figure 1.3 Reproduced from Newman and Taylor.85 Schematic demonstrating temperature dependence of the 
nucleation, growth, and overall crystallization rates for undercooled melts. 
The overall temperature-crystallization rate curve is influenced by both nucleation and 
growth rates. The nucleation rate increases with the degree of undercooling. It reaches a maximum 
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and then decreases as the temperature increases. The crystal growth rate, on the other side, show a 
maximum at a higher temperature than that for the nucleation. However, the extent of impact the 
crystal growth and the nucleation have on the overall crystallization process vary from one drug 
to another. As a result, the temperature dependence of crystallization rate is determined by the 
dominating process. A two-phase temperature dependence was observed for crystallization of 
lidocaine in a Duro-Tak® 87-2287 transdermal patch.86 The temperature dependence is shown in 
Figure 1.3.  The crystallization induction time m  of lidocaine was used to express the rate of 
nucleation J87. The longer the induction time, the smaller the rate of nucleation.   
! = n/m  (1.15) 
where K is a constant and that the induction time is inversely proportional to the nucleation rate. 
According to Arrhenius reaction velocity equation:79  
 ! = # exp − ∆)\*+ exp	(− ∆)p*+ )  (1.16) 
where A is the pre-exponential factor, k is Boltzmann’s constant, ∆,8 and ∆,q are the activation 
energies to develop stable nuclei and for molecular diffusion, respectively. In Figure 1.4, the 
temperature dependence of the nucleation rate at various drug concentrations (40 to 70 %) exhibits 
a two-phase log linear dependence below and above a transition temperature. The transition 
temperature was correlation with the magnitude of ∆,8  and ∆,q . Throughout the temperature 
evaluated, ∆,q is much greater than ∆,8, suggesting the crystallization is dominated by diffusion-
controlled nucleation. However, there was a sharp jump in ∆,8  at the transition temperature, 
marking the potential changes in crystallization mechanisms. A discrepancy between the 
experimental results and the classical theory of nucleation is that the observed ∆,8  is not 
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dependent on degree of supersaturation. What caused the sharp transition in the temperature 
dependence needs further investigation.  
 
Figure 1.4 Reproduced from Cui and Frank.86 A plot of rsm and VH< for lidocaine crystallization from Duro-Tak® 
87-2287.a 
Temperature can also influence where crystals appear throughout the thickness of the 
patches.  The growth of estradiol in Duro-Tak® 87-2196 was monitored through optical 
microscopy and the crystals were only found in the middle third of the polymer.10 J.Zeng simulated 
the location of nuclei and crystal growth in a PSA with a uniform 10% estradiol with a low and 
high temperature parameter kbT (0.3 and 0.9, respectively).88 With a high temperature parameter, 
the crystallization started in the middle of matrix and with a low temperature parameter, the grains 
were shown to evenly distribute throughout the thickness of the transdermal patch. At the 
beginning of the simulation, fluctuation of grains resulted in a few nuclei of critical size. These 
nuclei grew rapidly, accompanied by a drastic reduction in the solution concentration of the drug 
																																								 																				
a	Reprinted	from	Isothermal	crystallization	kinetics	of	lidocaine	in	supersaturated	lidocaine/polyacrylate	pressure	
sensitive	adhesive	systems,	94(9),	Cui	Y,	Frank	SG,	2039-2048.,	Copyright	(2005),	with	permission	from	Elsevier.	
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and Ostwald ripening of the grains. At low temperature, diffusion was too slow to sustain crystal 
growth; while only a few grains kept growing at a high temperature. One of the limitations of the 
study is that the drug molecule and the matrix polymer were assumed to be equal-sized. The 
molecular weight of polymer is usually 100-1000 times greater than the drug molecule. Another 
limitation of the study is that only 10% drug load was considered so no inference was given as to 
how drug load would influence the distribution of the crystals within the matrix.   
The typical Arrhenius relationship does not hold as temperature increases. The most 
common model to describe the temperature dependence of structural relaxations (or viscosity) 
above Tg is Vogel-Tamman-Fulcher (VTF):  
m = 	 mtG uNvNwNv  (1. 17) 
where m  is the mean molecular relaxation time, mt  is the relaxation time consistent for the 
unrestricted material, D is the strength parameter, and Vt  is the zero mobility or Kauzmann 
temperature. The equation demonstrates the strong dependence of relaxation time on temperature.  
 
1.3.2.6 Effect of Humidity on Crystallization 
The impact of environmental humidity on the crystallization of amorphous systems is 
manifested as increases in both rates and the overall extent of crystallization. The presence of water 
usually reduces the glass transition temperature (Tg) of amorphous systems, which may lead to 
increased molecular mobility. The nucleation rates and crystal growth rates of felodipine from 
amorphous PVP films increased with storage relative humidity.89-90 In these systems, the Tg of the 
polymer is much higher than that of the drug, so the Tg depression of these films was pronounced 
in the presence of moisture.    
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In another study, the physical stability of medicated (ibuprofen, salicylic acid and aspirin) 
acrylic adhesive transdermal films were found to decrease with the relative humidity. It was 
postulated that the absorbed water would decrease the solubility of drug in polyacrylate pressure 
sensitive adhesive Duro-Tak® 87-4287.91 The dependence of drug solubility on humidity was 
explained by a change in the equilibrium between dissolved drug, drug bound to polymer via H-
bonding and crystalline drug, as is shown in Figure.1.5.  During dynamic vapor sorption (DVS) 
experiments, water molecules replaced drug molecules that ware bound to polymers and thus 
increased the portion of free dissolved drug available for forming drug crystals. Even though this 
study proposed a method to calculate drug solubility based on the water sorption isotherm, no 
direct quantitative measure of the drug solubility/crystalline content was provided. Experimentally, 
the maximum drug concentration where no crystal was observed over a 4-month period was used 
as the apparent solubility.  
 
Figure 1.5 Reproduced from Chenevas-Paule and Dodou.91 Different states of the drug in the acrylic matrix.b 
																																								 																				
b	Reprinted	from	Development	of	a	Predictive	Model	for	the	Long-Term	Stability	Assessment	of	Drug-In-Adhesive	
Transdermal	Films	Using	Polar	Pressure-Sensitive	Adhesives	as	Carrier/Matrix,	165(3),	Chenevas-Paule	C,	Wolff	H-
M,	Ashton	M,	Schubert	M,	Dodou	K,	1293-1301.,	Copyright	(2017),	with	permission	from	Elsevier.	
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1.3.2.7 Surface and Bulk Crystallization 
The surface profile of amorphous solids is particularly important for transdermal drug 
delivery.92 Transdermal patches possess a relatively large contact area with the site of delivery. 
Therefore, the rate and extent of crystallization of the solid surfaces can have significant impacts 
on the application of a patch onto the skin and thereby influencing the efficacy of medication. The 
rate and the extent of crystallization at the solid surfaces is influenced by the physical and chemical 
properties of the surrounding environment, thermal history and processing conditions.93  
Surface mobility,94-95 surface energy and surface tension96-97 are among a number of 
physiochemical properties that are key to the instability of amorphous solids on the patch-air 
surfaces. The crystallization is often faster at the free surface than in the interior98 due to molecular 
mobility of the glassy materials.99-101 The surface diffusion of small organic molecules were used 
to infer molecular mobility. C. W. Brian and L. Yu used surface grating to study the surface 
diffusion of glass Nifedipine.102 They found the surface diffusion of Nifedipine is at least an order 
faster than bulk diffusion at 12K below glass transition temperature. In addition, the crystallization 
is dominated by surface kinetics. A good correlation was found between the surface crystal growth 
rates and surface diffusion rates.  
The effects of a range of thermodynamic, kinetic and molecular parameters on the bulk and 
surface stabilities of amorphous films were evaluated in another study.103 Molecular mobility was 
found to have the greatest influence among all the proposed parameters. The commonly used 
indicator Tg, fragility of the amorphous drug and the theoretically predicted drug-polymer 
solubility showed very limited influence on the bulk and surface stability. The order of bulk 
crystallization tendency of the four model drugs were the same with that of surface crystallization 
tendency. However, direct comparison between surface and bulk crystallization was not available 
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because different preparation methods were used for the two crystallization modes: melt quenching 
was used to study bulk crystallization while spin-coating produced films where the surface profile 
was measured. Inclusion of heat and solvents in the two preparation methods can have large 
impacts on the thermal history and molecular mobility of the samples.  
Polymers were widely used to stabilize amorphous solids. The inhibition effect of polymers 
on drug crystallization at the surface is different from that in the bulk. Tian and coworkers tracked 
the growth of felodipine crystals detected from a filmy solid dispersion with PVP prepared on 
glass slips.104 Co-milled API and PVP were melted on a glass slide covered with a top slip. The 
cover slip was later removed in the case of cover-free samples to observe surface growth; while 
the bulk crystal growth was observed without removing the cover slip. The onset time for 
crystallization was recorded. Crystallization was very fast at high drug concentrations (>90% w/w) 
and the onset times were similar between the surface crystallization and bulk crystallization. The 
polymer was reported to have a limited ability to slow down crystallization no matter it is on the 
surface or in the bulk when the concentration of polymer is low. The observation was consistent 
with Kestur’s study in which 3% PVP had a slight impact on reducing the rate of crystallization of 
felodipine.105 Nevertheless, the cover-free samples showed a faster onset compared to that of the 
double-sided samples at lower drug loadings (35 to 80 % w/w). Tian and coworkers pointed out 
that the faster rate of crystallization on the surface was attributed to the greater molecular mobility 
at the surface. In a similar study, Felodipine migration towards the PVP film surface was observed 
when the solid dispersions were stored in high humidity environment.62 A substantial increase in 
the percentage of drug in the surface may promote to faster onset of surface crystallization in 
transdermal patches. Drug migration process of the thin films is illustrated in Figure 1.6. 
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Figure 1.6 Reproduced from Qi, Moffat and Yang.62 Schematic illustration of drug migration process of the thin 
films.c 
 
1.3.2.8 Morphology and Polymorphism of Crystals 
Crystals may present diverse morphology and have modified chemical composition within 
the transdermal patches. Optical microscopy revealed that β-estradiol crystals formed two 
distinctly different morphologies in a single layer inside the Duro-Tak® adhesive matrix: needle-
like crystals and aggregates around the needles.106 A Raman microscopic study showed the needle-
like crystals contain the adhesive component and the aggregates are modified crystal form of 
estradiol. It was proposed that the crystallites of the polymer act as nucleation sites for growth of 
drug crystals in the aggregates and therefore the Raman spectra of the aggregates contain 
signatures of both the crystalline β-estradiol and the adhesive. A study further investigated the 
physical form of the estradiol aggregates. A splitting of the C-O peak at 1284 and 1294 cm-1 was 
attributed to the existence of at least two types of crystal forms: an anhydrous form and a 
hemihydrate form.107  
 
																																								 																				
c	Adapted	with	permission	from	Early	Stage	Phase	Separation	in	Pharmaceutical	Solid	Dispersion	Thin	Films	under	
High	Humidity:	Improved	Spatial	Understanding	Using	Probe-Based	Thermal	and	Spectroscopic	
Nanocharacterization	Methods,	10(3),	Qi	S,	Moffat	JG,	Yang	Z,	918-930.,	Copyright	(2013),	American	Chemical	
Society.	
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1.3.3 Analytical Techniques for the Quantification of Drug Crystallization in 
Pharmaceutical Films 
The physical constituents of drug in the transdermal patches have impacts on the release of 
drug to the skin. The crystallization in pharmaceutical films needs to be measured to inform the 
efficacy and long-term stability of the products. An accurate and reliable analytical method is very 
useful in formulation development.  The formation of crystalline drug can be visually observed by 
optical or polarized microscopy. However, the quantification of the crystalline API is very 
challenging because the development of a calibration requires the amorphous and crystalline 
phases to be separately prepared and weighed. Nevertheless, complete separation of the adhesive 
from the crystals is extremely difficult.108 Therefore, only a few reported the quantitative method 
development for transdermal systems109 whereas the quantification of crystalline drug in 
amorphous solid dispersions have been demonstrated for powders110-111 and tablets.18, 112-113 An 
overview of application of multiple analytical techniques, focusing on Near-infrared and Raman 
spectroscopy for the quantification of crystalline drug content in pharmaceutical film is presented 
in this section.  
 
1.3.3.1 Optical Microscopy 
Polarized light microscopy (PLM) is frequently used to determine the presence or absence 
of crystalline components in amorphous systems. This technology is based on the idea that an 
isotropic crystalline material refracts a light beam into two perpendicular rays as a result of changes 
in the refractive index along the optic axes of the crystal. This phenomenon is called double 
refraction or birefringence. As amorphous materials do not exhibit birefringence behavior, this 
technology is very sensitive to the presence of crystalline materials in amorphous solid dispersions. 
This technique can detect single particles, which makes it suitable for initial screening for 
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crystallization. Tian and coworkers tracked the growth of felodipine crystals detected from a filmy 
solid dispersion prepared on glass slips using PLM.114 The growth rate was calculated from the 
change in distance from the edge of felodipine crystal to a fixed center point on a 2D image. 
However, a drawback of this method is that PLM does not account for crystals distributed 
vertically to the glass slide. Another limitation of qualitative or quantitative optical microscopy 
analysis is the problem of sub-sampling. In order to provide a quantitative measure of crystalline 
drug in a transdermal patch, a large number of images need to be acquired. Therefore, PLM is 
more appropriate for qualitative purposes.  
 
1.3.3.2 Dynamic Vaper Sorption 
Dynamic vapor sorption (DVS) provides information about location and speed of solvent 
sorption.115 These information can then be related to amorphous content in solid dispersion, 
crystallization and specific API-polymer interaction in solid dispersion.116 It is equipped with a 
microbalance capable of measuring changes in sample mass lower than 1 part per million.117  
Amorphous materials have a greater affinity for water than crystalline materials because both 
adsorption onto the surface as well as absorption into the bulk occurs in an amorphous material .118 
The amount of water taken up during adsorption is dependent on the available surface area whereas 
the amount of absorption is determined by the total mass of  amorphous solids.119 Once the 
amorphous content is determined from adsorption, the crystalline content can be calculated by 
subtracting the amorphous content from the total drug content.  
The extent of crystallization can also be measured directly by DVS. A weight loss can be 
recorded during crystallization as the absorbed water is expelled from the amorphous materials. 
However, crystallization of APIs is not always accompanied by water loss. One exception is 
hydrate formation and another example is secondary absorption of the expelled water by 
	31 
	
hydrophilic polymer in a solid dispersion.120 Additionally, water sorption is proportional to the 
surface area of non-reactive components.121 Thus, the moisture sorption is not specific to the 
amorphous component. Another conflicting factor is the formation of hydrogen bonds between 
APIs and polymers. It can reduce the number of water binding sites available during dynamic 
water sorption experiment and thus the sorption isotherm. Considering these factors, DVS is a 
semi-quantitative technique for crystalline content quantification and it is usually used in 
combination with other analytical techniques that are sensitive to phase changes.  
 
1.3.3.3 X-ray Diffraction 
Among several significant tools for solid-state characterization, powder X-ray diffraction 
is the most definitive technique for detecting crystalline drug(s) in ASDs. This technique probes 
the periodicities in molecular structures, thus implying the amorphous state  by the absence of 
order.122 The diffraction patterns of the crystalline solids are more distinctive compared to the halo 
diffraction patterns of the amorphous solids. The incident beam is diffracted by multiple layers of 
atoms creating constructive and destructive interference of the X-ray beams. Constructive 
interference is formed when the path difference between diffracted beams is equal to an integer 
multiple of the wavelength. This is described by  Bragg’s law:123  
sx = 2az{s|  (1.18) 
where d is the distance between the planes in a crystal, expressed in angstrom, n is the order of 
reflection, and x  is the wavelength of X-rays. Assuming the experimentally measured signal 
intensities attributed to the crystalline and amorphous materials are proportional to the crystalline 
and amorphous fractions of the sample, the percent crystallinity (}89) of SDs in the sample can be 
estimated:124  
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}89 = ~\×<tt~\Ä~Å 	 (1.19) 
where Ç8 and Çcare the crystalline and amorphous intensities, or area contributions. Quantification 
of crystalline components in ASDs can be achieved by measuring the characteristic crystalline 
peak intensities, or the integrated peak area of the principal crystalline peaks125 or the whole 
spectrum. An internal standard (IS) is often mixed with the sample before the diffraction pattern 
is recorded. The peak intensities of lines unique to the crystalline drug and to IS peak are used to 
calculate a ratio, which relates to the degree of crystallinity. Using an IS helps to solve the 
problems of peak overlap and background scattering.126 Although this quantitative approach has 
been successfully applied on pharmaceutical powders, the solid-state evaluation of pharmaceutical 
films via XRD is largely qualitative.127-130 
The determination of low quantities of crystalline API in ASD is not trivial. The 
dependence of signal on particle size is a confounding factor in the quantification of crystalline 
contents in powder samples. The diffraction line shape is also affected by the crystallite size and 
sample packing. Microcrystalline and nanocrystalline materials typically generate broadened 
peaks. Sometimes multiple peaks merge into a single broad peak that is easily confused with the 
amorphous halo. The influence of variations in the lattice strain and particle size on the integrated 
peak intensities is significantly reduced compared to that on the line shape; thus, the integrated 
peak intensities are more appropriate for quantitative analysis.131  As to quantitative analysis of 
crystalline content in transdermal films, changes in particle size and porosity accompanying drug 
crystallization can cause variations in the signal. Other issues related with XRD, such as preferred 
orientation and micro-absorption,132 could also present in transdermal patch systems.  
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In addition to quantitative analysis of crystalline materials, the XRD can be used to 
characterize the structure and miscibility of amorphous compounds via a method termed atomic 
pair distribution function (PDF).133-135 This method has been suggested to provide finger-printing 
patterns for amorphous APIs and local packing information of APIs in the disordered solid 
states.136 Powder X-ray diffraction spectra of ASDs are Fourier transformed into PDFs and then 
compared to the theoretical PDF profiles calculated from the amorphous polymer and amorphous 
API. PDF is the weighted probability of finding two atoms separated by their distance r:  É 1 = 4415 Ñ 1 − Ñt       (1.20) 
 where Ñt is the average atom number density of the structure, Ñ 1  the atom pair density for X-
ray scattering, and g(r) represents the characteristic inter- and intramolecular distances found in a 
given material. It is calculated by Fourier transform of the reciprocal space structure function S(Q): , 1 = 	 5> Ö R Ö − 1 sin Ö1 aÖâ	Xcät     (1.21) 
where S(Q) is the structure factor and Q is the magnitude of the scattering vector. The Qmax is the 
momentum transfer resolution of the diffraction experiment.  
The PDF patterns of two different types ASDs are plotted as a function of r in Figure 1.7. 
If the PDF pattern in the dispersion is well described by the characteristic distances in the API and 
polymer, the dispersion contains isolated single components, i.e. there is a phase separation as 
shown in Figure 1.7(B). If a clear deviation of sample PDF from the theoretical profile is observed, 
the components in the solid dispersion are miscible.137 Likewise, drawing a plot of residuals 
between the theoretical and measured PDFs helps to provide information about the drug-polymer 
miscibility. The relative contribution of API and polymer to the overall PDF is correlated to their 
relative weight percentages. A statistical interval can be drawn around the residuals to determine 
miscibility. Alternatively, a fitting algorithm can be used to determine the goodness of fit for the 
	34 
	
same purpose.  However, there is a lack of consensus on the threshold for determining the degree 
of fitting.137  
 
Figure 1.7 Theoretical and measured PDF profiles of a (A) molecularly dispersed ASD; (B) phase separated ASD. 
M.D. Moore developed a method for drawing statistical inferences from the differences 
between experimental PDF transforms of PXRD data. The experimental error was estimated and 
passed along through the mathematical transformation. Specifically, the experimental errors 
comprised experimental imprecision and sample inhomogeneities. Meanwhile, there were 
uncertainties due to data corrections, as well as artifacts incurred from Fourier transformation. The 
resulting estimates of propagated errors for individual PDFs were combined to define uncertainty 
intervals surrounding the residuals. It helped to distinguish differences between PDF patterns 
arising from structure sources rather than from random error.138   
 
1.3.3.4 Differential Scattering Calorimetry 
Differential scanning calorimetry (DSC) is a powerful technique for understanding the 
miscibility and crystallinity of chemical components in amorphous systems. The sample is heated 
at a linear rate through its melting point in the conventional DSC. A pure crystalline material shows 
a single sharp endothermic peak at the melting temperature. Amorphous materials are 
(A) 
 
(B)	
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characterized by an endothermic event called glass transition. Recrystallization of the amorphous 
phase sometimes takes place during a DSC measurement resulting in an exothermic peak. The 
exothermic recrystallization peak and endothermic melting peaks are often used to calculate the 
crystalline fraction of the drug.139 The crystalline content in a given sample can be estimated from 
the heat of crystallization or enthalpy of fusion:140  }89 = ∆ã∆ãv ×100%  (1.22) 
where ∆é is the enthalpy of fusion of the sample and ∆ét is the enthalpy of fusion of the 100% 
crystalline standard. The calibration samples consist a series of physical mixtures of  amorphous 
API, crystalline API, and excipients.131 
Differential scanning calorimetry is very useful for understanding crystallization kinetics 
and the influence of environmental factors on physical stability of solid dispersions. The 
recrystallization kinetics of amorphous solid dispersion of efavirenz-polyvinylpyrrolidone was 
measured by DSC. Melting enthalpy of the solid dispersions were used to calculate relative 
crystallinity. An improved Avrami equation was taken to describe the recrystallization kinetics of 
fenofibrate in hot-melt extruded solid dispersion containing  hydroxypropyl cellulose and HPC.141 
This equation assumes the nucleation rate decreases as the available nucleation sites are 
consumed.142 In another study, differential scanning calorimetry analysis was performed to 
quantify the crystallinity of naproxen in a solid dispersion formulated with glycol. Such solid 
dispersions were coated by different grades of PEG to study the effect of coating on the rate of 
crystallization. The crystallinity after storage in 75% RH decreased as the molecular weight of the 
PEG coatings was increased.143 
Samples in the form of films are particularly suitable for DSC measurement because close 
contact between a film and the sample holder is achieved with a flat film. In this way, effective 
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heat conduction between the pan and the material can be ensured. However, films need to be folded 
when multiple pieces are used in a single pan; loose packing may result in poor heat transfer. In 
the case of particle bearing films, the effect of sample heterogeneity on DSC measurement must 
not be ignored.  
 
1.3.3.5 Near Infrared and Infrared Spectroscopy 
Spectroscopic methods such as near-infrared and infrared spectroscopy have been used for 
crystalline phase quantification in pharmaceutical solid dosage forms. IR bands of most 
pharmaceutical ingredients, such as O-H stretching vibration, C=O stretching vibration and OH 
vibration, are highly specific and they are associated with the chemical structure and inter 
molecular interactions of samples. The absorption bands in the NIR region include overtones and 
combinations of fundamental vibrations of the- CH, -OH, C-O, -NH and S-H functional groups 
present in most active pharmaceutical ingredients. Near infrared spectroscopy has been used to 
quantify amorphous content in a crystalline matrix144 and physical mixtures of crystalline and 
amorphous drug in the presence of excipients.145 Vibrational spectroscopy based techniques have 
been demonstrated to have equal or better sensitivity than XRD for crystalline content 
quantification in powders.146 Other advantages of IR based techniques  include non-
destructiveness and rapid analysis.  
Despite the benefits that NIRS may bring, NIR spectra contain board and overlapping 
peaks that are difficult to resolve. Additional challenges are associated with the unexpected signal 
variations caused by physical variations such as density, particle size, and sample presentation.147-
149 Therefore, qualitative and quantitative analyses are often performed with multivariate methods 
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including principle component analysis (PCA), multivariate curve resolution (MCR), classical 
least squares (CLS), and partial least squares (PLS).  
The penetration depth of NIR light determines the sampling volume obtainable by a NIR 
instrument. If the sampling volume is too small compared to the unit dosage form, there is a sub-
sampling problem. The typical penetration depth of NIR radiation in powders is between 0.1 and 
2.0 mm.150-151 The actual penetration depth strongly dependents on the chemical composition, 
particle size, powder density and wavelength. The refractive index in transdermal patches is more 
uniform than that in a turbid medium(powders, tablets and suspensions).152  
NIR imaging serves as a versatile adjunct to the NIRS for studying the spatial distribution 
of components in a formulation, including crystalline components. The distribution of crystalline 
tulobuterol in a reservoir-type transdermal film was investigated by T. Sakamoto and coworkers.153 
The second derivative peaks were used to probe the presence of the crystals in transdermal films. 
A time-course NIRS measurement showed the intensities of the peaks corresponding to the 
crystalline drug increased from zero to maxima in six weeks.  
 
1.3.3.6 Raman Spectroscopy 
Raman spectroscopy is one of the most common techniques for probing solid phase 
transformations.154 A monochromatic laser beam interacts with molecular vibration, phonons or 
other excitations in the sample, resulting in energy changes of the laser photons.155-156 The 
molecular vibration, rotation or phonon mode of the irradiated material shifts the energy (or 
frequency)  of the incident photon. The vibrational modes of Raman spectra are useful for probing 
changes in molecular structure, molecular conformation and packing changes during 
crystallization. Molecules in crystals are arranged in a repetitive structure and thus bonding 
environment of Raman-active bands is the same in each molecule.157 The Raman peaks of 
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amorphous phases are less intense than peaks from crystalline forms. Additionally, peak shifts are 
often observed upon crystallization. These phase changes are often used in quantitative analysis to 
assess the physical stability of amorphous solid dispersions.   
Both Raman spectroscopy and Raman imaging have been used to detect crystallization 
from amorphous solid dispersions.158-159 An confocal Raman microscope is capable of focusing an 
excitation laser beam to an area as small as 50 um160 in diameter. providing images revealing the 
spatial distributions of API and polymers in ASD films. Tian and coworkers employed Raman 
imaging to examine the phase compatibility felodipine and a polymer at various compositions.160 
The polymer is either HPMCAS, Soluplus®, or PVP. The drug weight fraction varied from 35 to 
90 %. The solid dispersions were prepared by co-milling powders of the drug and the polymer into 
homogeneous mixtures. The mixtures were melted and cast onto glass slips. The distributions of 
the components in the formed film were monitoring by a Raman imaging system. A phase map 
was obtained during an annealing process. The spectral features at 1750 – 1450 cm-1 were used to 
correlate Raman spectra to the crystalline form of felodipine.  In the first few days a uniform phase 
map showed a poor correlation with the crystalline form, suggesting the film was mostly 
amorphous. This is followed by an increase in the amount of crystalline felodipine from the edges 
to the entire film.  
The applications of Raman spectroscopy for solid state analysis within polymeric films 
have been increasing over recent years.  Changes in the crystallinity of drug in hot-melt extrudates 
can be monitored by Raman spectroscopy to identify out-of-spec products.161-162 Solid dispersion 
coupled with 3-D printing were proposed to produce films containing amorphous paracetamol and 
Eudragit L100-55.162 Crystalline particles were found on films by a confocal Raman microscope. 
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The crystalline API was not from recrystallization of the amorphous form but was the residual, un-
sintered drug powder that had not been effectively cleared away after the previous batch.  
In-line monitoring of crystallization has been implemented in batch crystallizations. 
However, the applicability of Raman for physical stability assessment in film samples is limited 
by several drawbacks including interference due to fluorescence, sample heating and presence of 
strong peaks in Raman spectra from organic solvents. These drawbacks may adversely influence 
the quantitative capability of Raman instruments for crystalline content determination in 
transdermal patches. 
Spectral preprocessing helps to reveal the spectral differences between different forms of 
drugs. The residual drug crystallinity in a melt-extruded spironolactone-Eudragit E solid 
dispersion was estimated using confocal Raman imaging and transmission Raman spectroscopy.157 
Classical least squares (CLS) scores were computed based on the spectra of pure Eudragit E, 
amorphous spironolactone, and crystalline spironolactone. Samples made with different extrusion 
temperature, screw speed, residence time and drug loading, were produced to ensure a varying 
degree of crystallinity. All the samples were screened by XRD and DSC. Nevertheless, no 
reference value of crystallinity was obtained because the pure amorphous drug was too unstable 
under the storage condition. Due to a lack of reference methods, the author pointed out that 
crystallinity determined are only suitable for preliminary comparisons.  
Quantification of crystalline content in amorphous systems is challenging since the 
physical mixtures used to build calibration are either unavailable or too unstable.21 A method that 
does not require calibration would be advantageous. Classical least squared (CLS), multivariate 
curve resolution (MCR) and band target entropy minimization (BTEM) are among the most 
common multivariate methods for estimating crystallinity. Band target entropy minimization is a 
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self-modeling curve resolution technique for elucidating phase compositions. E. Widjaja found 
trace crystalline griseofulvin particles in Kollidon VA64 dispersions via this technique.22 The goal 
of BTEM method is to reconstruct the underlying spectral shape of amorphous and crystalline drug 
in the absence of priori knowledge of crystallinity. This method not only enabled minor crystalline 
domains of griseofulvin to be detected, it also differentiated the two polymorphic forms of the 
drug.  
 
1.3.3.7 Other Analytical Considerations 
The conventional approach to characterize the physical states in transdermal patches 
involves applying multiple complementary analytical techniques. Using multiple techniques for 
accurate identification of crystalline phase in the presence of amorphous or dissolved phase is 
often necessary because it is very challenging to obtain specific differences in long-range order 
using a single technique.  Despite the many successful examples of accurate phase identifications, 
drawing information from multiple instruments has many limitations.  The destructiveness and 
time-consuming nature of one or more conventional techniques reduce the reliability of test results.   
As the destructive method needs to be the last step of the analyses, a sample has waited for a long 
time before the final test.  Conflicting results generated from different analytical techniques may 
occur as the amorphous drug continues to recrystallize over the time frame of the analyses. 
Additionally, interpretation of phase information is generally complicated because different 
analytical techniques demonstrate diverse degrees of sensitivity to the crystalline and amorphous 
phases.  
Accurate determination of crystallinity in transdermal films with low dose APIs is limited 
by the detection limit of conventional techniques. The detection limits of XRD for crystalline APIs 
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is typically 2.0 – 5.0 %.163-164 The detection limit of solid-state nuclear magnetic resonance 
spectroscopy (SSNMR) is less than 0.5 %. By far the highest sensitivity for crystal drug 
determination was reported for second-harmonic generation microscopy. Second-harmonic 
generation guided analysis exhibited a detection limit as low as parts per trillion.165 
Amorphous phase separation is considered one of the events preceding crystallization of 
amorphous drugs from ASDs. The detection of phase separation in ASD requires high spatial 
resolution. The size of separated domains detectable by DSC measurements is about 30 nm.134, 166 
The diffraction limit of traditional microscopy is about 1 to 10 microns. The birefringence 
microscopy is very sensitive to crystals, but it cannot differentiate different amorphous 
components. It was postulated that pair-wise distribution function coupled with XRD has the 
capability to distinguish nano-size phase separations. The use of time of flight-secondary ion mass 
spectrometry (TOF-SIMS) to characterize ASDs is limited to the 1-2 nm exterior layer of a film.167 
Therefore, the volume of interrogation only constitutes a tiny fraction of the sample. The detection 
limit of second harmonic generation microscopy is about 5 orders of magnitude lower than that of 
optical microscopy.168 A solid-state nuclear magnetic resonance spectrometer is able to detect 
molecular-level movements down to the angstrom scale. 
 
1.3.3.8 In-line PAT Applications 
The incorporation of PAT tools into continuous film manufacturing processes is clearly 
preferred by PAT guidelines as it exhibits tremendous advantages for process monitoring and 
automation.152 Advantages include rapid and non-destructive measurements, and the ability to 
detect multiple properties. Physical stability is an important quality attributes that can be analyzed 
by several spectroscopic methods, as described in previous sections. Near-infrared spectroscopy 
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and Raman spectroscopy have been increasingly used to determine the critical product quality 
attributes in pharmaceutical film products such as hot-extruded transdermal films. 
F. Hammes implemented a reflectance infrared spectrometer for in-line monitoring of an 
nicotine oral thin film during coating process for an oral thin film production.61 M.T.Isam 
presented a transmission NIR method for the monitoring of indomethacin transformation from the 
crystalline state to the amorphous state during hot-melt extrusion. J. Zhang used Raman 
spectroscopy to monitor drug content in strip film manufacturing. The Raman method developed 
by J.Zhang et.al. was robust to sensing location, substrate speed, and film thickness.169 The 
crystalline content of hot-extruded samples can be related to multiple product properties and 
process variables. These variables include zone temperatures of the barrel, screw speed and 
residence time.170 The relationship between the residual drug crystallinty157 and the process 
variables, such as zone temperature of the barrel, screw speed and residence time, can be acquired 
by an in-line spectroscopic tool to ensure the product quality. 
 
1.4 Stability Testing of Transdermal Patches 
The purpose of the stability testing of a drug product is to help select adequate formulation 
and primary packaging material, and to determine shelf life and storage conditions for the drug.171 
The attributes of the drug products that are susceptible to change during storage and are likely to 
influence quality, safety, and efficacy should be included in stability studies.172 The stability 
testing of transdermal patches can be conducted at three conditions: long term (12 months), 
intermediate (6 months), and accelerated storage conditions (6 months) according to ICH 
guidelines.172 The accelerated stability studies are conducted at 40 °C ± 2 °C and 75 % RH ± 5% 
RH representing an elevated temperature and a high relative humidity.  
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Physical stability testing is an integral part of the stability studies for DIA transdermal 
patches. The detection of crystallization of drug in PSA patches are only done with qualitative 
analytical methods. Appearance of crystals were monitored visually and microscopically as an 
indicator of physical instability. The process of crystallization was generally described by the 
classical theory of nucleation theory,86, 173-174 using data generated from DSC, XRD and isothermal 
calorimetery.86, 175-176  
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Chapter 2 : Preparation and Characterization of Drug-in-adhesive 
Transdermal Patches 
2.1 Background and Introduction 
The phase composition of the API exerts a profound effect on the solid-state properties of 
the DIA system. Thus, characterization of the active pharmaceutical ingredients in the solid state 
is critical to the development of useful transdermal formulations. To ensure the physical integrity 
and consistent release of a DIA system containing a metastable form of API, the physical properties 
of the drug, excipients and their mixtures must be thoroughly evaluated.   
The quality tests for transdermal systems are outlined in USP <3> ‘Product Quality 
Tests’.177  Among a dozen frequently tested product quality attributes, visual examination of 
crystallization by conventional optical or polarized microscopy remains the primary method for 
physical stability evaluation in transdermal patches. The visual examinations of crystalline 
components are subjective to the judgement of the individuals.  Additionally, crystallization has 
been known to negatively impact the in-vitro and in-vivo drug release. Therefore, the 
crystallization must be monitored throughout the development of transdermal formulation. A 
quantitative spectroscopic method for crystalline content determination of the API offers 
tremendous advantages over the traditional solid-state characterization methods. These advantages 
include rapid and non-destructive analyses, low detection limits for crystalline APIs, and 
simultaneous analyses of all chemical components in a formulation.   
Practical investigations of a spectroscopic method for solid-state quantification in 
pharmaceutical solids were required in the early-stage development. They include a 
comprehensive understanding of the pharmaceutical system, a thorough investigation of potential 
effects of formulation variables on a calibration model, and quantification of analytical capability 
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of the instrument.178 The second chapter addresses the first two aspects by introducing the DIA 
system and laying out the experimental methods used to test the physiochemical properties of the 
DIA system. These pieces of information regarding an analytical procedure is of particular 
importance to the understanding of the variability of the sample system, the dynamic range, the 
regression model, and limits(s) of quantification.179 Ibuprofen and the adhesive were mixed at 
different concentrations and prepared at changing thickness levels. Samples were tested in terms 
of the quality attributes and physical stability. The quality attributes include thickness and 
thickness variations, weight and weight variations, drug content and content uniformity. The 
solubility of the API in the adhesive was calculated to determine the physical stability of the DIA 
patches. This chapter also investigated the influence of the thickness on the NIR signal or the 
Raman signal. This study helps to determine whether the patch thickness need to be controlled 
prior to crystalline content quantification. 
 
2.2 Experimental Methods 
2.2.1 Materials 
The proposed drug-in-adhesive transdermal patch is composed of three layers: a liner (3M 
ScotchpakTM 9755 release liner, 3M, St. Paul, MN, USA), a drug-bearing adhesive layer and a 
backing layer (3M ScotchpakTM 1012 backing, 3M, St.Paul, MN, USA). The model API is (RS)-
ibuprofen (Thermo Fisher Scientific, Waltham, MA, USA), a nonsteroidal anti-inflammatory 
analgesic that reduces fever and treats pain. The adhesive Duro-Tak® 2052 (Henkel Corporation, 
Stanford, CT, USA) is an acrylates copolymer with free -COOH groups. The target formulation 
contains ibuprofen (23.5% w/w) and Duro-Tak® 2052 (76.5% w/w). Four batches were made on 
different days to determine the intra and inter batch variations in API content and thickness.  
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DIA patches were prepared at predefined levels (Table 2.1) to evaluate the effect of patch 
thickness on the signal. The API content was calculated from the dry mass of the adhesive solution 
(determined from non-volatile content). Prepared transdermal patches were cut to a size of 1.5 cm 
by 1.5 cm for physical and chemical evaluations.  
Table 2.1 Composition and thickness of DIA patches used to evaluate the influence of thickness on Raman and NIR 
signal 
Batch number Drug load (%, w/w) 
Adhesive load 
(%, w/w) Thickness (mm) 
P1 23.5 76.5 0.40 
P2 23.5 76.5 0.50 
P3 23.5 76.5 0.55 
P4 23.5 76.5 0.60 
Blank 0.0 100.0 0.55 
 
2.2.2 Preparation of DIA Patches by Solvent Casting 
Ibuprofen powder was dissolved in ethyl acetate to produce a 40% w/w solution. The 
solution was stirred until the drug was fully dissolved. Duro-Tak 2052® was added into this 
solution and homogenized overnight. The solution was cast onto a release liner when the solvent 
content of the solution was approximately 12 % w/w. The final solvent content was estimated 
based on mass of the final solution. A gardener knife was used to achieve consistent thickness. 
Casting was followed by drying in the hood at 25 °C for 2 hours. Then they were further dried at 
55 °C for 24 hours until weight changes were less than 1 % w/w. The oven temperature was kept 
below the melting temperature of the drug (76 °C) but above the glass transition temperature of 
the drug (-42 °C). The adhesive layer was laminated with a backing film. The prepared patches 
were equilibrated at 25 °C and 32 ± 2 % RH for 24 hr prior to physical characterization. 
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2.2.3 Characterization of DIA Patches  
2.2.3.1 Non-volatile Content of PSA 
The non-volatile content (NVC) of the adhesive solution was determined gravimetrically. 
Accurately weighed aliquots (1.0 g) of adhesive solutions were dried at 75 °C for 24h and weighed 
to determine non-volatile content.  
èêë %,í/í = 	 cHì H(8Hì)cHì   (2.1) 
where î is the mass of an adhesive solution plus a weighing pan prior to drying, ï is the mass of 
the same weighing pan, c is the mass of the dried adhesive plus the weighing pan.  
 
2.2.3.2 Thickness and Weight Variation 
Each patch was measured with a digital micrometer (Micromaster IP54, BROWN & 
SHARPE TESA, North Kingstown, RI, USA) and a digital balance (AX504 Delta Range, Mettler-
Toledo, LLC, Columbus, OH, USA) across three locations to determine the thickness variations 
within a single patch. Six patches from each batch were characterized in terms of thickness and 
weight variation within each batch. Four batches of DIA films were prepared on three separate 
days to determine the thickness and weight variations across batches. 
 
2.2.3.3 Drug Content 
Samples were weighed after release liners were peeled off. The mean weight of the backing 
was determined by weighing 10 backings of the same size (1.5 by 1.5 cm) and was subtracted from 
the mass of each DIA patch. Each DIA patch sample was placed in a 50 mL beaker and 20 mL 
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PBS 7.4 solution was added. The sealed beaker was homogenized in a shaker (Branson 8210 
Ultrasonic Cleaner, Branson Ultrasonics Corp., Danbury, CT, USA) for 24h. The shaker speed and 
temperature were set at 30 rpm and 40 °C, respectively. The resulting solution was added to a 100 
mL volumetric disk. A 1:20 dilution was performed by adding 5mL of solution to 100mL 
volumetric disk. Filtered solution was analyzed at 223 nm by an ultraviolet-visible (UV-vis) 
spectrometer (Hewlett Packard 8453 UV-Visible, Agilent Technologies, Santa Clara, CA, USA). 
The drug content was expressed as the solid weight fractions of drug/DIA layer (%, w/w).  
 
2.2.3.4 Drug-adhesive Interactions 
The compatibility of the drug and the adhesive was evaluated using Fourier-transform 
infrared (FTIR) spectroscopy. The appearance of new absorption bands, changes in peak positions 
and alterations in peak intensities indicate interactions between the chemical components.180  The 
samples were dried and measured using a Spectrum BX FTIR Spectrometer (Perkin Elmer, 
Waltham, MA, USA) with an attenuated total reflectance sampling accessory. Measured samples 
included: ibuprofen powder as received, Duro-Tak® 2052 films prepared using the procedure 
described in 2.2.2, and DIA patches with a drug-adhesive weight ratio of 1:1. The samples were 
measured with three replicates. A background scan was collected and subtracted from each sample 
spectrum. Absorbance spectra were recorded in the transmission model in the mid-IR region 
(4000-400 cm-1) with 64 scans and a 4 cm-1 spectral resolution.  
 
2.2.3.5 Solubility of the drug in the Adhesive 
The equilibrium solubility of ibuprofen in Duro-Tak® 2052 was calculated using two 
methods. The first method was based on the limiting form of the Flory equation:181  
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ñ< = GH(<ÄóI) = GH(<.26ÄBIôN×(öIHöD)D)  (2.2) 
where ñ<	is the volume fraction of the solute (can be used to estimate mass fraction), õ<is the 
interaction parameter, ú<is the molar volume of the drug, ù<is the solubility parameter of the drug, ù5is the solubility parameter of the acrylate-vinyl acetate copolymer, R is the gas constant (8.314 
JK-1mol-1), and T is the temperature (298K).  
The second method for calculating the solubility of ibuprofen in Duro-Tak® 2052 was the 
regular solution theory equation. 182 Scatchard-Hildebrand equation relates the activity of a drug 
to the solubility parameters of the polymer and the supercooled liquid of drug: 
ln cIäI = 	 7IüDD†+ (ù< − ù5)5 (2.3) 
where î5 is the drug activity, °<is the drug molar fraction and ñ5is the polymer volume fraction. 
Assuming the heat capacity of the drug is constant, the drug activity can be approximated by: 
rsî5 = − ∆ã_¢£(+` H+)†++`  (2.4) 
where ∆éU§• is the enthalpy of fusion (J.mol-1) of the drug and VX is the melting temperature (K). 
The drug mass fraction in PSA can be estimated by °<	based on Equation (2.3) and (2.4), 
assumingñ5 ≈ 1:  
rs°< = − ∆ã_¢£ +` H+†++` − 7IüDD†+ (ù< − ù5)5  (2.5) 
Solubility parameter values were determined based on Hoftyzer and van Krevelen’s group 
contribution method: 
ùq = ßp®©   (2.6) 
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ù™ = ßZ®D©  (2.7) 
ù´ = ¨≠®©  (2.8) 
where ùq ù™, and ù´ are the solubility parameter contribution of dispersion, polar and hydrogen 
bonding components, Æq:and Æ™: are group contribution to the dispersion and polar components, Ø´: is the hydrogen bonding energy, and V is the molar volume. ù; is the total solubility parameter 
estimated from the three solubility parameter contributions:  
ù; = ùq5 + ù™5 + ù5´ (2.9) 
Patches used to experimentally verify the calculated solubility were prepared with varying 
mass fractions (11,13,15,17,19% w/w) of drug. The patches were stored at 32 ± 2% RH and 25 °C 
for six months to determine the maximum concentration at which no crystallization was detected 
by a polarized light microscope (Olympus BX-51 light microscopy). This storage condition 
represented the center design point used in Chapter 5. The degree of supersaturation of drug in the 
adhesive was calculated by taking the ratio between the target drug concentration and the 
equilibrium solubility.  
 
2.2.3.6 Absence of Crystalline Drug in Freshly Prepared DIA Patches  
A polarized light microscope (Olympus BX-51 light microscopy, Tokyo, Japan) was used 
to confirm the absence of crystallinity in freshly prepared DIA patches. Additionally, the absence 
of crystalline API was determined by an X-ray diffractometer (XRD) (X’Pert Pro MPD system, 
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PANalytical B.V., Almelo, Netherlands). The step size was 0.017 o 2θ over a range of 2-100 o 2θ 
and the irradiation time per step was 51.04 s.  
 
2.2.3.7 Distribution of the Crystalline Drug 
Transdermal patches made according to design point P2 (Table 2.1) were stored at 25 °C 
Crystallization of ibuprofen was monitored by a microscope. The samples were cut, and the cross-
section areas were observed to determine the distribution of crystallized drug.   
 
2.2.4 Effect of DIA Patch Thickness on Spectral Signal 
2.2.4.1 Spectral Data Collection 
a. Near-infrared  
DIA patches were measured using a diffuse transflectance setup shown in Figure 2.1. A 
white Teflon plate was used as a reflector.  Eight detectors were displaced at 45 degrees from 
normal relative to the plane of the sample, as is shown in Figure 2.1(B). The liner side of the patch 
was placed towards the measurement window while the backing layer was placed towards the 
Teflon plate. Each patch was positioned at the center of the widow of a NIR spectrometer (XDS 
Rapid Content Analyzer, Metrohm, Eden Prairie, MN, USA). The spot size of the instrument was 
17.25 mm, and 32 spectra were averaged to produce one spectrum. The loss in absorbance due to 
scattering of light from the particles inside the patches was corrected by subtracting a spectrum of 
the sample measured using a black tape. The NIR absorbance of a patch sample is calculated taking 
account of the patch thickness:  
#8 = [− log 	 ~QH~u~≤H~u + log 	 ~≥H~u~≤H~u ]× <5¥	   (2.10) 
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where Ç- is the intensity of a sample, Çµ is the intensity of the sample measured on a Teflon plate, Çd is the intensity of a dark measurement and Ç∂ is the intensity of the sample measured with a 
black tape. l is the thickness of each transdermal patch.  
 
Figure 2.1 NIR measurement setup. A: side view; B: top view. 
	
b. Raman  
Raman spectra of the samples was carried out with the Kaiser RXN2®-Hybrid Raman 
system (Kaiser Optical System, Ann Arbor, MI, U.S.). The light backscattered from the sample 
was collimated by an objective lens to achieve a 1.5 mm diameter laser spot size. The spectra in 
the range of 150-1890 cm-1 were acquired with a resolution of 4 cm-1. The acquisition time was 
set at 5 s with 8 co-adds to provide adequate signal compared to noise. Multiple spectra were 
collected on every patch: four collected on the corners and one taken in the center. Two linear 
stages driven by a motion controller (Ensemble®, Aerotech Inc., Pittsburgh, PA, USA) and two 
brushless motors (BMS60, Aerotech Inc., Pittsburgh, PA, USA) accurately located the sampling 
locations for each sample. Figure 2.2 demonstrates the Raman setup for patch measurements.  
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Figure 2.2 Experimental setup of a Raman spectrometer for DIA transdermal patch measurements.  
	
2.2.4.2 Data Preprocessing 
Spectral data of both instruments were treated by several preprocessing methods including 
standard normal variate (SNV), normalization to film thickness and normalization to unit area. The 
correlation coefficients between the spectra (raw and preprocessed) and patch thickness were 
compared. A suitable preprocessing method was selected based on the ability of the method to 
reduce the influence of patch thickness on signal.  
 
2.3 Results and Discussion  
2.3.1 Appearance, Thickness and Weight Variation 
The non-volatile content of adhesive Duro-Tak® 2052 was 49.60 ± 0.83 % w/w, which was 
used to determine the amount of drug needed for the calibration design (Chapter 5). All the patches 
made according to the target formulation were transparent and colorless. The thickness and weight 
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of patches at the target formulation (23.5% w/w API and 0.55 mm, or P3 in Table 2.1) are shown 
in Figure 2.3. The variations were within ± 10% of the nominal values.  
 
Figure 2.3 Intra and inter batch thickness variations of DIA patches. 
 
2.3.2 Drug Content and Uniformity 
The drug content and content uniformity are shown in Table 2.2. Relative standard 
deviations of the drug contents were below the acceptable values (15 %) specified in USP <905> 
for uniformity of dosage units in single-unit containers, indicating dose uniformity of the patches 
was reached.  
Table 2.2 A summary of the content uniformity of four batches of DIA patches  
Batch Drug content (%, w/w) 
Content uniformity 
(RSD %) n =10 
1 25.9	±	1.24 4.77 
2 23.4	±	1.16 4.96 
3 24.3 ± 1.09 4.49 
4 23.9	±	1.28 5.36 
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2.3.3 Drug-adhesive Compatibility  
  
Figure 2.4 FTIR spectra of ibuprofen powder, blank adhesive (Duro-Tak® 2052) and DIA patch composed of 50% 
w/w ibuprofen. Spectra were scaled to assist visual comparisons.  
The FTIR spectra of ibuprofen and Duro-Tak® 2052 are shown in Figure 2.4. The 
characteristic IR absorption bands of ibuprofen at 1708, 1512, 1452, 1420, 1268 cm-1 indicate the 
presence of C=O stretching, C-C ring vibration, C-H asymmetric bending and C-H scissoring, CH-
CO deformation, and C-O stretching.183 These peaks were all observed without shifts in the 
presence of adhesive, suggesting ibuprofen is compatible with the adhesive.   
2.3.4 Equilibrium Saturation Solubility of Ibuprofen in Duro-Tak® 2052 
Table 2.3 Solubility parameters for ibuprofen in a Duro-Tak® system 
Model 
drug 
Molecular 
weight 
(g/mol) 
Density 
(g/cm3) 
Molar 
volume 
(cm3/g) 
Total δ of 
drug184 
Total δ of 
polymer185 
Estimated 
drug 
solubility 
(%, w/w) a 
Estimated 
drug 
solubility 
(%, w/w) b 
Ibuprofen 206.30 1.18 174.83 19.36 21.51 18.89 16.17 
 
a. Calculated using the limiting form of Flory’s equation (Equation 2.2)  
b. Calculated using regular solution equation (Equation 2.5)   
The physicochemical properties and solubility parameter values for the model drug are 
listed in Table 2.3. Drug solubility in the adhesive patch was dependent on the difference in 
solubility parameters between the drug and the polymer. The patches loaded with the drug at a 
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concentration above the equilibrium solubility will recrystallize. The estimated solubility of 
ibuprofen (+/-) in Duro-Tak® 2052 was 18.89% w/w based on Flory’s equation and was 16.17% 
w/w using the regular solution equation. The solubility calculated using the Flory equation was 
over-estimated and 16.17% was used moving forward. The Flory equation is not valid when there 
are specific molecular interactions between drug and polymer.   
The crystallization of ibuprofen in patches loaded with varying drug concentrations were 
observed after six months of storage at 25 °C and 32 % RH. In Figure 2.5, white crystalline drug 
particles were observed in patches with a drug load equal or greater than 15% w/w. This result was 
consistent with the solubility estimated from the regular solution equation. However, at 
concentration greater than 19% w/w, there is a noticeable increase in the amount of the crystals. 
 
Figure 2.5 A photo of ibuprofen DIA patches with varying drug concentrations. The drug concentrations of the 
patches from the top row to the bottom row are 11, 13, 15, 17, 19 and 23.5% w/w.  
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2.3.5 Absence of Crystalline Drug in Freshly Prepared DIA Patches 
All the patches freshly prepared according to the target formulation were transparent and 
colorless. There was no birefringence via a polarized microscope. The XRD diffractogram of a 
freshly prepared DIA patch is shown in Figure 2.6, along with the XRD pattern of ibuprofen 
powder. The signal of the freshly prepared DIA patch at 12.4 2|  was also observed in the 
diffraction patterns of the liner and the backing. The signature XRD pattern of ibuprofen was 
absent in the diffractogram of the DIA patch, suggesting that either the drug did not crystallize, or 
the amount of crystallized drug was below the detection limit of the XRD diffractometer. The 
signal of the patch is very similar to the pattern of the liner. The liner is made of a semi-crystalline 
material, polyethylene terephthalate (PET).186  
 
Figure 2.6 XRD diffraction patterns of a freshly prepared DIA patch, ibuprofen powder and patch components. 
	
2.3.6 Distribution of Crystalline Drug 
Cross-sections of crystallized transdermal patches were checked under the microscope. 
Note that the liners were removed from the patches prior to microscopic examination. The 
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photomicrographs were taken at a magnification level of ´40. In Figure 2.7 (B) and (C), the 
crystallized drug, shown as the bright areas under the polarized light, were found near the surface 
of the drug-in-adhesive layer and around the edges of the patches. Inside the patch, the 
crystallization occurred primarily at the liner-adhesive interface. The bright line is the backing 
layer of the patch. Along the edges, the irregular surfaces caused by cutting can serve as 
heterogeneous nucleation sites.  
 
Figure 2.7 A: Schematic illustrating where a film was trimmed for microscopic observation; B: An optical image of 
the cross-section of a crystallized DIA patch ; C: A polarized light microscopic image of the cross-section of a 
crystallized DIA patch. 
 
2.3.7 Effect of Thickness on Spectral Signal 
2.3.7.1 Effect of Thickness on NIR Signal  
The effect of light scattering appears to be less significant in DIA patches comparing to 
that in turbid media. This is because patches composed of a continuous phase of drug and adhesive 
contained fewer scattering centers such as crystals and pores. Therefore, Beer’s law was used to 
explain the relationship between the NIR absorbance and thickness of DIA patches:  
#: = ∏ï:π:  (2.11) 
where #:and ï: are the absorbance and thickness of i-th sample, ∏ the absorptivity of the analyte, 
which is wavelength dependent, and	π: is the concentration of the analyte in that sample. Figure 
2.8 shows the NIR spectra of patches with thickness varied between 0.40 and 0.60 mm. Based on 
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Beer’s law, the NIR absorbance should increase linearly with the sample thickness. The correlation 
between the raw NIR spectra and patch thickness is illustrated by the blue curve in Figure 2.9.  
An abrupt change in the correlation coefficient at 1100 nm is due to the transitioning of 
signal recorded from a silicon (400-1100 nm) detector to a lead sulfide (1100-2500 nm) detector 
in the NIR spectrometer. The correlation between the raw spectra and thickness was greater than 
0.7 at most places above 1100 nm.  
Several preprocessing methods were explored to reduce the correlation between thickness 
and NIR spectra. The green curve represents the correlation calculated after the spectra were 
corrected by the measured patch thickness. The correction involves dividing each spectrum by the 
thickness value of the corresponding sample. It reduced the correlation to 0.6 from 0.8 at regions 
above 1100 nm. However, the thickness correction increased the correlation in the spectral region 
of 600-1100 nm. Normalization to unit area is a preprocessing that divides each spectrum by its 
norm so that the sum of the absorbance at all wavelength equals to 1. Standard normal variate 
(SNV) reduces the overall intensity differences between spectra by removing the mean followed 
by dividing the standard deviation of each spectrum. Normalization and SNV both reduced the 
correlation between thickness and the NIR signal. The SNV gave a slightly lower correlation 
(<0.5). The difference across the NIR spectra shown in Figure 2.8 (A) was effectively removed 
after SNV was applied (see Figure 2.8(B)). 
	60 
	
 
Figure 2.8 NIR spectra of DIA patches with changing thickness. A: raw spectra; B: spectra preprocessed by SNV. 
 
Figure 2.9 Correlation coefficients calculated between the patch thickness and raw or preprocessed NIR spectra. 
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2.3.7.2 Effect of Thickness on Raman Signal 
 
Figure 2.10 Raman spectra of DIA patches with changing thickness. A: raw spectra; B: spectra preprocessed by 
SNV. 
Baseline changes were observed as patch thickness changed. Figure. 2.10 (A) shows the 
Raman spectra of patches(Table 2.1) with a thickness varying between 0.44 and 0.60 mm. An 
explanation for the phenomenon is that the sample surface was shifted from the focal plane as the 
thickness was increased. However, the differences in the intensity were effectively removed by 
applying spectral preprocessing. Figure 2.10 (B) showed the spectra of patches of different 
thickness were overlapped after SNV was applied.  
 
Figure 2.11 Correlation coefficients calculated between patch thickness and raw or preprocessed Raman spectra. 
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The raw spectra of the patches showed negative correlations with the patch thickness. This 
observation is illustrated in Figure 2.11. Spectral correction by dividing thickness values did not 
reduce the spectra-thickness correlation. It enhanced the correlation, which suggests the spectral 
variation associated with the thickness changes is not a simple linear function of the path length. 
Normalization to unit area and SNV were used to minimize the scale and baseline differences. The 
two preprocessing methods led to very similar amounts of reduction in the correlation coefficients. 
These methods were used for reducing the influence of thickness on signal during the calibration 
development.  
 
2.4 Conclusions 
Ibuprofen transdermal patches were prepared using Duro-Tak® 2052. The prepared 
transdermal patches were evaluated for drug-excipient compatibility (FTIR), drug content 
uniformity, weight variations, and distribution of crystalline drug in the patches. The developed 
formulation demonstrated consistent quality attributes within and between batches. The DIA 
patches prepared were initially free of crystals, as was confirmed by XRD results. After 
crystallization reached equilibrium, the crystalline drug was found primarily at the interface 
between the liner and the DIA layer. The results of these preliminary experiments revealed 
ibuprofen is supersaturated at 23.5% w/w in the DIA system with a drug solubility of 
approximately 16% w/w. Both NIR and Raman signal of the transdermal patches were highly 
correlated with the patch thickness. Proper data preprocessing is required to reduce the influence 
of thickness on the spectral signal.   
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Chapter 3 : Determination of Analytical Feasibility for Crystalline 
Content Quantification in DIA Patches. 
3.1 Background and Introduction 
Physical mixtures of crystalline and amorphous drug are frequently used to build 
quantitative calibrations to determine crystalline content of APIs in solid dispersions. Unlike 
powder samples that can be prepared by blending, the adhesive polymer is very tacky, making the 
blending of adhesive and drug difficult and unlikely to result in appropriate dispersion of the drug 
particles. Mixing the crystalline drug and the adhesive polymer requires additional mechanical 
force or heat to blend the materials, which are likely to change the physical state of the solids.  
The problems described above can be solved by a method that separately prepares film 
layers containing different phases of the API and combines them. This preparation method helps 
to achieve a known percent crystallinity that is needed for calibration, because the quantities of the 
crystalline and the amorphous drug are known at the time of preparation.  
This chapter describes a coating-based method for spiking crystalline API into DIA patches. 
The suitability of spiked samples to be used as calibration samples for crystalline content 
quantification was demonstrated. The samples spiked with drug crystals and the samples naturally 
recrystallized must have similar physiochemical properties as well spectral responses. Spiked 
samples were made by spraying accurately measured amounts of crystalline drug onto liners via 
spray coating of an aqueous drug suspension. Samples with naturally formed crystals were 
prepared by dissolving ibuprofen in the Duro-Tak® adhesive at a concentration above the 
equilibrium solubility and allowing the ibuprofen to recrystallize.  
The geometric distribution of the spiked crystals in the spiked samples was characterized 
and compared with the naturally crystallized samples in Chapter 2. In addition to having similar 
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physiochemical properties, the spiked samples must remain physically stable over a period long 
enough for solid-state characterization. The crystal growth (or dissolution) of the spiked crystals 
in DIA patches were observed by optical microscopy to determine the length of time during which 
recrystallization (or dissolution) of drug was insignificant.  The spectral similarity between the 
spectra of spiked and naturally recrystallized samples was demonstrated in Chapter 4.  
The coating uniformity of calibration samples is always important, but it is particularly 
important when the analytical technique samples only a fraction of the available patch area. When 
the spot size of analytical tool is larger than the size of a patch and the thickness of the patch is 
less than the path length of the light beam, the sampled volume is limited by the size of the patch. 
However, when the spot size is smaller than a patch, a lack of coating uniformity may increase the 
measurement uncertainty. Therefore, a study to determine the coating uniformity of spiked crystals 
was conducted.  
Both NIR spectroscopy and Raman spectroscopy are potential techniques for quantitative 
characterization of crystalline phase in transdermal patches. However, a comparison of the 
techniques for TDDS, based on figures of merits such as sensitivity, specificity and suitability of 
such methods has not been reported. This chapter demonstrates the analytical feasibility of 
vibrational spectroscopy (NIR and Raman) for quantitative study of ibuprofen crystallization in 
Duro-Tak® 2052. Instrumental sensitivity towards the two physical forms (supercooled liquid and 
crystalline solid) of the drug were measured. The sensitivity was defined as the change in signal 
intensity per unit change of concentration. The depth of penetration of the excitation laser beam in 
DIA patches was measured. Adequate sampling volume must be ensured for representative 
sampling.  Optimization of measurement settings was performed. The goal was to find the best 
measurement scheme that maximizes signal intensity while retaining a relatively short 
	65 
	
measurement time. The chapter develops the analytical foundations that are used in the next 
chapter.  
 
3.2 Experimental Methods  
3.2.1 Preparation and Characterization of Spiked Samples  
3.2.1.1 Materials 
The drug and adhesive were dissolved and cast onto backing layers according to the method 
described in Chapter 2.  Crystalline drug particles were coated onto liners. Patches from the three 
levels of crystalline contents (3 replicates per batch) were selected to represent the low, medium 
and high levels of crystallinity. The backing layer coated with dissolved drug and the liners spiked 
with crystals were combined to prepare patches with desired crystallinities (Table 3.1).  
Table 3.1 Composition of calibration and test sets using a full factorial design 
 
 
 
  
 
 
 
3.2.1.2 Preparation of Liners Coated by Crystalline Drug  
Ibuprofen powders were passed through a sieve with openings of 250 µm. Agglomerates 
were removed to reduce the risk of blocking the spraying nozzle during coating of the suspension. 
A 1.5% w/w ibuprofen aqueous suspension was prepared using de-ionized water. The suspension 
Sample Crystallinity (%) 
Crystalline- 
Sprayed API 
(%, w/w) 
Solvated API 
(%, w/w) 
Adhesive Dry 
Weight 
(%, w/w) 
C1 4.0 1.0 23.5 75.5 
C2 17.5 5.0 23.5 71.5 
C3 25.4 8.0 23.5 58.5 
A1 0.0 0.0 17.0 83.0 
A2 0.0 0.0 23.5 76.5 
A3 0.0 0.0 30.0 70.0 
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was homogenized on a magnetic stirrer overnight. The suspension was sprayed onto pre-weighed 
3cm-by-3cm liners to achieve desirable coating weights using a fluidized bed spraying gun and a 
peristaltic pump. The nozzle of the spraying gun has an opening of 1.5 mm to allow for the passage 
of drug suspension. The air pressure was set at 1.0 bar, or 105 Pascal. The spraying rate was set at 
3 g of suspension per min. A hot plate (45 °C) was placed at the bottom of the liner to facilitate 
the drying of water. The distance between the spraying nozzle and the hot plate was 36 cm. The 
setup of the spraying station is demonstrated in Figure 3.1. The amount of drug sprayed increased 
linearly with the coating time. The empirical relationship is:  
m = 0.050t  (3.1) 
where m is the mass (mg) of the drug sprayed and t is the coating time in seconds. The relationship 
was used to determine the coating time used for coating a crystalline content on a liner. The mass 
of the drug sprayed is dependent on the actual spraying settings such as air pressure, pump rate 
and homogeneity of the drug suspension. During coating, all these settings were kept constant. 
 
Figure 3.1 Schematic demonstrating the powder coating process. A drug suspension containing 1.5% w/w ibuprofen 
in water was sprayed onto liners. The water was dried by compressed air and a hot plate set at 45 °C. 
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3.2.1.3 Physical Stability of Spiked Crystalline API  
A drug-bearing adhesive was coated onto the powder coated side of a liner to form a drug-
in-adhesive patch. The crystal growth of the spiked crystalline particles was monitored by an 
optical microscope every 10 min over a period of 150 min following the lamination. The procedure 
to determine the induced crystal growth rate is illustrated in Figure 3.2. The optical image shown 
in Figure 3.2 (A) was converted to a gray image shown in Figure 3.2 (B). The histogram 
demonstrating the distribution of the pixels in the grayscale image was used to select the cutoff 
value for converting the gray image to a binary image. The cutoff value is indicated by the arrow 
in Figure 3.2 (D). The cutoff value marks the maximum change in the slope of the frequency 
distribution of the grey image. In the binary image of Figure 3.2 (C), the white and the black pixels 
represent crystals and the background, respectively.  The void spaces within each particle were 
switched to white pixels (Figure 3.2 (E)) as the pixels within the circumstances of each particle is 
a part of the crystal. The conversion from an optical image to a binary image allows the number 
of pixels occupied by the crystalline drug to be counted. T-tests (α=0.05) were used to test the 
statistical significance between mean areas of crystals at two successive time points. The time 
point at which projected area was significantly larger than that of the picture taken at the initial 
time point was the crystallization induction time (tind). The spectroscopic measurements were 
performed within the time window of 0-tind.  
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Figure 3.2 Conversion of an optical image to a binary image for calculating the area representing the drug crystals. 
A: An optical image; B: A grey image; C: A binary image; D: The frequency distribution of pixel intensity of the 
binary image; E: Black pixels inside the crystalline particles were switched to white pixels. 
 
3.2.1.4 Coating Uniformity  
The coating uniformity of the sprayed crystalline particles was evaluated by an optical 
microscope using a magnification of 40´. This magnification was selected because the size imaged 
was the same as the size probed by the Raman system. Binarization was conducted using the same 
procedure described in 3.2.1.3 to calculate the area representing the crystalline drug. The RSDs of 
the crystalline drug areas were calculated from four replicates at each concentration. Only liners 
with RSDs less than 10% were selected moving forward.  
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3.2.2 Determination of Analytical Feasibility  
3.2.2.1 Determination of Penetration Depth of the Raman System  
The penetration depth of the laser beam in the sample is a determinant of the sampling 
volume. Raman spectroscopy have been shown to have limited penetration in solid turbid media.187 
However, in transparent samples such as DIA transdermal patches, the light will penetrate into 
deeper layers without significant elastic scattering. The feasibility of the Raman analyzer to probe 
the whole sample volume was established experimentally by observing the signal change in a 10-
layer patch system. This method keeps the sample thickness and focal distant constant.188 A 
polytetrafluoroethylene (PTFE) film was sandwiched between 10 layers of DIA patches containing 
23.5% w/w of ibuprofen in Duro-Tak® 2052. The signal from the PTFE was tracked as the PTFE 
film was moved from the top to the bottom of the pile (see Figure 3.3).  
 
Figure 3.3 Schematic demonstrating samples used for depth of penetration determination.  
 
3.2.2.2 Determination of Instrument Sensitivity  
a. Instrument Sensitivity  
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Figure	3.4	Schematic	demonstrating	the	contents	of	crystalline	and	solvated	drug	of	spiked	patches	used	
to	determine	instrumental	sensitivity.	
Analytical sensitivity was calculated as the signal change per unit change of analyte 
concentration. The crystalline content was varied by 1.0, 5.0 and 8.0% w/w based on a 120 mg 
patch. The crystalline drug was coated according to the method described in 3.2.1.2. Three 
replicates were made at each crystallinity level. To determine the sensitivity of the instruments for 
detecting changes of crystallinity when drug was dissolved in the adhesive matrix, the solvated 
API contents were kept constant (23.5% w/w). The composition of spiked samples is illustrated in 
the upper panel of Figure 3.4. The three crystalline levels are designated in Figure 3.4 by samples 
C1, C2 and C3. The spectral responses were recorded by the NIR and the Raman systems. The 
sensitivity was determined as the mean spectrum difference between samples with changing 
crystallinity divided by the difference in crystalline contents: 
 RGsz{∫{ú{∫ª	∫º	π1ªz∫îr = ΩGîs(	 æ\DHæ\I∆ø¿DI + æ\@Hæ\D∆ø¿@D + æ\@Hæ\I∆ø¿@I )   (3.2) 
where }8: is the mean spectrum of a sample with a crystallinity of ë:, e.g. }85 represents the mean 
spectrum of samples with a crystallinity of 5.0% w/w. ∆¡Y:¬ is the difference in the crystalline 
content of drug between the ith sample and the jth sample. 
Similarly, the sensitivity of analytical tools to changes in the solvated drug (metastable 
form) was determined by measuring DIA patches with drug dissolved in the adhesive at 
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concentrations varying from 17.0 to 30.0% w/w. The compositions of samples A1, A2 and A3 are 
illustrated in the bottom panel of Figure 3.4.  The sensitivity for the solvated API is calculated as 
follows: 
RGsz{∫{ú{∫ª	∫º	zºrúî∫Ga	#√Ç = ΩGîs(	 æƒDHæƒI∆øƒDI + æƒ@HæƒD∆øƒ@D + æƒ@HæƒI∆øƒ@I )   (3.3) 
where }≈: is the mean spectrum of a sample with a particular solvated API content #:, e.g. }≈< 
represents the mean spectrum of samples with a drug content of 17 % w/w. ∆¡≈:¬ is the difference 
in the solvated drug content between the ith and the jth samples. 
A univariate sensitivity was calculated as the sum of sensitivity across a certain wavenumber or 
wavelength region. Univariate sensitivity of the Raman system or the NIR system to two forms of 
ibuprofen were calculated. The results were compared with the sensitivity of an XRD method.  
 
b. Effective Resolution  
Effective resolution (0)  is another useful measure of relative sensitivity of dissimilar 
analytical techniques. It is the ratio between the vector of sensitivity and the vector of noise:  
0 = ( -¨∆∆S:•«)H<  (3.4)  
The effective resolution has a unit of concentration. It represents the minimum discernible 
concentration attained by the analytical system. It allows the comparison of analytical methods 
regardless of the specific technique, equipment and scale. 189 The noise of the measurements is 
calculated from the standard deviations of repeated scans of the same sample. Experiments were 
repeated for all concentration levels (A1-A3, C1-C3).  
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3.2.2.3 Instrument Selectivity 
PCA analysis was used as a discriminant tool to visualize the separation of the spiked and 
solvated samples in PC space.  All the samples shown in Figure 3.4 were measured by the NIR 
system and the Raman system. The wavenumber region 676-1225 cm-1 was selected for Raman 
and 1550-2250 nm was selected for NIR because these regions contain the signature peaks of the 
API. NIR and Raman data were both preprocessed with SNV and mean-centering. For each 
analytical technique, a PCA model was constructed. The number of PCs were determined from the 
percent variance explained by the PCA models. The incorporation of appropriate number of PCs 
allowed the PCA models to explain more than 95% of the spectral variance for each technique. 
The angle between the center planes of the two clusters that separately contain A1-A3 and C1-C3 
expressed the orthogonality between the two sample sets in the PC space. The two clusters were 
fitted by 95% confidence ellipsoids. More specifically, the angles between the normal vectors of 
the confidence ellipsoids were calculated	and used to express the degree of independence between 
the samples A1-A3 and samples C1-C3.  
Selectivity expresses the extent to which a particular method can be used to determine a 
particular analyte in mixtures or matrices without interferences from other components of similar 
behavior.190 A PLS model was developed from the spectra of the spiked samples (C1, C2 and C3) 
to predict the crystalline contents of samples with varying solvated API contents (17, 23 and 30% 
w/w). If the PLS model accurately determines the crystalline content in the presence of variations 
of solvated drug content, the model is selective to the crystalline component. The samples used in 
this part of study is shown in Figure 3.5.   
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Figure 3.5 Schematic demonstrating the compositions of patches used to determine instrument selectivity. 
	
One-way ANOVA was used to determine if there is any statistical difference between the 
predicted crystalline contents of the patches with different solvated API contents. The statistical 
tests used a P-value of 0.14 for drawing statistical significance using multiple t tests. The type I 
error rate for multiple t-tests is inflated as the number of comparisons increases. Therefore, a 
corrected type I error was used instead:    
» = 1−(1 − »)X (3.5) 
where » is type I error for an independent comparison and »=0.05, m is the number of comparisons.  
 
3.2.2.4 Sample Measurements  
a. Raman and NIR measurements 
The NIR and Raman measurements of transdermal patches were carried out using the 
setups demonstrated in Section 2.2.4.1. Each sample was repeatedly scanned for three times with 
and without repositioning to estimate the reproducibility and repeatability of the method. One NIR 
spectrum was collected for each patch. The spot size of the NIR system (17.5 mm) was larger than 
the size of a patch. The Raman system has a spot size of 1.5 mm, which is smaller than the size of 
a sample. Therefore, five spectra were collected on one patch: four collected on the four corners 
and one taken in the center. The obtained spectra were averaged to give one spectrum per sample.  
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b. XRD measurement 
Diffraction data of transdermal films were collected using an X’Pert Pro MPD system 
(PANalytical B.V., Almelo, the Netherlands) in Bragg-Brentano reflection mode, equipped with a 
Cu anode (λ = 1.5406 Å), an elliptical mirror, and an X’CeleratorTM detector. The operating voltage 
and amperage were 45 kV and 40 mA. Samples were mounted flat on a ring holder. Samples were 
rotated throughout the experiment to allow for full volume interrogation. Irradiation time was set 
to 60.05 s per step with an angular step size of 0.017 °2θ over a range of 2 to 60 °2θ.  
 
3.3 Results and Discussion 
3.3.1 Coating Uniformity 
The homogeneity of the coated crystalline drug particles was examined. Images of patches 
with crystalline content of 1.0, 2.5, and 5.0% w/w are shown in Figure 3.6. The relative standard 
deviation was 6.72, 5.37, and 6.79% for patches with crystalline level of 1.0, 2.5, and 5.0% w/w, 
suggesting uniform coating of the crystalline particles was achieved.  
 
Figure 3.6 Microscopic photos of patches with A: 1.0% w/w; B: 2.5% w/w; C: 5.0% w/w sprayed crystalline API.  
 
(A)		 (B)		 (C)		
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3.3.2 Physical Stability of Coated Patches 
The crystal growth induced by the spiked crystalline API in the 23.5% w/w DIA patches 
was revealed by image analysis. The change of area taken up by the crystals as a function of time 
post lamination is illustrated in Figure 3.7. In the first 40 mins, there was a minimum change of 
the area attributed to the crystalline API. From 40-150 min, the area of the crystals increased. The 
crystallization induction time was determined to be about 50 min. The area after this time point 
was significantly greater than that of the initial time point. The result suggested all analytical 
measurements should be conducted within the crystallization induction time, which is about 40-
50 min.  
 
Figure 3.7 Crystal growth of spiked drug represented by a change in the area of the crystalline particles. 
 
3.3.3 Penetration depth of the Raman System 
Depth of penetration is a measure of how deep an electromagnetic wave penetrates a 
sample. It is critical for determining where the information is generated from the sample. 
Penetration depth helps to select the appropriate sampling strategy. If penetration depth is large, 
whole volume sampling can be achieved without sampling from both sides of the samples. 
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Polytetrafluoroethylene (PTFE) was used to measure the penetration depth of laser beam in DIA 
patches. Polytetrafluoroethylene has a few sharp and resolved peaks that are not overlapped with 
the components of the DIA patches. The signal intensity of PTFE reduces with an increasing 
number of patches placed between the PTFE and the probe. The Raman spectra of PTFE and 
stacked films are illustrated in Figure 3.8. Peaks of the PTFE film at 734 and 1381 cm-1 were 
selected for their high intensities.  Additionally, the DIA patches do not present any interference 
in these regions.  
 
Figure 3.8 Raman signal of a PTFE film overplayed with 10 DIA patches. 
The signal of the PTFE film decreased when more DIA layers were added. The intensities 
of peaks at 734 and 1381 cm-1 were normalized by the maximum intensities of the peaks, i.e. when 
the PTFE was on the top of the pile. The resulting ratios shown in Figure 3.9 decreases with the 
thickness. In depth of penetration studies, the signal intensity is often found to decrease with the 
thickness of the sample until it reaches a plateau, which signify the light can no longer penetrate 
the sample.  However, the ratio has not reached a plateau in Figure 3.9; whereas the normalized 
intensity is close to zero at the highest overlayer thickens (10 layers). Adding DIA layers would 
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not further reduce the signal from the PTFE film. The Raman signal can be detected through 8-9 
layers of DIA films. The information depth was evaluated using the point where the substrate 
signal was reduced to 1/e or 37%. The information depth was estimated to be about 1.6-2.0 mm 
for the Raman system, which is much greater than the thickness of a DIA patch (0.4-0.6mm). 
Therefore, it was concluded that the Raman system can be used to probe an entire patch.  
 
Figure 3.9 Intensity of PTFE at 734 and 1381 cm-1. The intensity was normalized to the spectra of films when the 
PTFE was placed on top of 10 layers of DIA films. 
 
3.3.4 Analytical Sensitivity  
3.3.4.1 NIR System 
a. Sensitivity to crystalline and solvated API  
The NIR spectra of DIA patches with 17 to 30% w/w of dissolved ibuprofen (samples A1-
A3) can be found in Figure 3.10 (A). There was an increase in the overall NIR absorbance due to 
the increase of API concentration in DIA patches. This increase is consistent with the Beer’s law.  
The difference spectra of patches with different solvated API contents, along with the spectrum of 
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supercooled ibuprofen, are displayed in Figure 3.11 (A). Similarities between the difference 
spectra and the spectrum of the supercooled liquid of ibuprofen can be observed. Meanwhile, 
increases in the crystallized API content not only increased the NIR absorbance around the peaks 
at 2200 nm, it also led to a decrease in the baseline near 1900-2100 nm. The baseline decrease was 
possibly caused by the increased backscatter from the crystals, causing the absorbance to decrease. 
However, it is not clear why the phenomenon was most pronounced in this wavelength region. The 
baseline decrease is shown in Figure 3.10 (B).  
The change in NIR signal per 1% w/w change of crystalline or solvated API is 
demonstrated in Figure 3.12 as a function of wavelength.  The extent of variation of NIR signal 
due to the crystalline API content is greater than that due to the solvated API. The univariate 
sensitivity, or the sum of sensitivities across all wavelength, for the solvated and the crystalline 
API are listed in Table 3.2. Note that the sensitivity to crystalline API is partially negative due to 
the baseline variations. The absolute values were used to calculate the univariate sensitivity. The 
ratio of the sensitivity between the two phases is about 2.66. Overall, the NIR system is more 
sensitive to the crystalline drug compared to the solvated drug. 
Table 3.2 A summary of univariate sensitivity and effective resolution for the NIR, Raman and the XRD systems 
 
NIR Raman XRD 
Sensitivity 
×104 
γ  
(%, w/w) 
Sensitivity 
×104 
γ  
(%, w/w) 
Sensitivity 
×104 
γ  
(%, w/w) 
Variables 2085-2225 nm (280) 667-946 cm-1(280) 16-20 ° (280) 
Solvated 2.77 0.41 1.56 1.86 NA  
Crystalline 7.36 0.31 5.34 0.69 1.20 5.27 
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Figure 3.10 NIR spectra of DIA patches with A: solvated API; B: crystalline API. Concentrations on the left column 
indicate the solvated drug contents and concentrations on the right column are the crystalline drug contents.  
 
Figure 3.11 A: Difference between NIR spectra of samples A1, A2 and A3; B: Difference between the NIR spectra 
of samples C1, C2 and C3. 
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Figure 3.12 Sensitivity vectors of the solvated API and the crystalline API determined from difference spectra 
shown in Figure 3.11. 
 
b. Effective Resolution  
The NIR system has shown good repeatability. This is demonstrated as a low spectral noise 
obtained by measuring patch samples repeatedly without repositioning. The standard deviations of 
the repeated scans were plotted for the patches with solvated API and the crystalline API in Figure 
3.13. The noise level of the samples with spiked crystalline API is a little higher than that for with 
solvated API, probably because the presence of the crystalline particles caused a greater extent of 
variations in the light scattering. The noise was particularly inflated at the wavelength region of 
2200 to 2500 nm.   
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Figure 3.13 Standard deviations of NIR spectra collected from patches with solvated API (23% w/w) and crystalline 
API (5.0% w/w). 
The ratios between the sensitivity (Figure 3.12) and the noise vectors (Figure 3.13) are 
illustrated in Figure 3.14. The effective resolution is the inverse of the sensitivity-to-noise ratio. 
The wavelength with sensitivity to noise ratio lower than 0.5 were excluded because the inverse 
approaches infinity as the sensitivity to noise becomes increasingly small. The effective resolution 
of the NIR system is lower than 1% w/w for the entire wavelength range. Therefore, the NIR 
system is sensitive to both the crystalline and the solvated API.  
 
Figure 3.14 Sensitivity to noise ratio of the NIR system to different API phases. 
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Figure 3.15 Effective resolution of the NIR system to changing crystalline and solvated API contents (The regions 
where sensitivity to noise ratio lower than 0.5 was excluded). 
	
3.3.4.2 Raman System 
	
Figure 3.16 A: Raman spectra of DIA patches with solvated API; B: Raman spectra of DIA patches with different 
levels of crystalline API; C: Difference between Raman spectra of samples A1, A2 and A3; D: Difference between 
Raman spectra of samples C1, C2 and C3.  
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The Raman spectrum of the pure crystalline phase of the API presents information about 
the long-range order of molecules. This can be seen in Figure 3.16 (B). Peaks at 1208, 833, 821, 
784, 746 cm-1 are related with the changes in crystalline drug content. Comparatively, changes in 
the solvated API concentration only led to subtle changes of Raman signal in the region near 1200 
and 900 cm-1(Figure 3.16 (A)). The difference between spectra of samples with different 
concentrations are shown in Figure 3.16 (C) and (D). Figure 3.16 (D) revealed some overlapping 
peaks between the spectral difference across samples C1-C3 and the pure crystalline ibuprofen. 
The similarities between the spectral difference across samples A1-A3 and the spectrum of the 
supercooled API is demonstrated in Figure 3.16 (C).  
The sensitivities per 1% w/w change of crystalline or solvated content is shown in Figure 
3.17. Overall, the Raman system is more sensitive to the crystalline drug than to the solvated drug. 
The ratio of the sensitivity between the two phases is about 6.4.  
 
Figure 3.17 Sensitivity of solvated API and crystalline API determined from difference spectra 
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Figure 3.18 Noise profile of the Raman system collected from DIA patches with a crystalline content of 2.4% w/w. 
 
The instrumental noise is characterized by the pooled standard deviation of the spectra 
obtained from repeated scans of the samples loaded with 23.5% w/w solvated API and 2.4% w/w 
crystalline API for 6 times. The noise is consistent across the wavenumber range under evaluation, 
as is shown in Figure 3.18. The noise profile is used to normalize the sensitivity associated with 
the Raman data to calculate the minimum discernible concentration (γ-1), which is referred to as 
effective resolution.191 The ratios between the sensitivity to noise at all wavenumbers are 
illustrated in Figure 3.19 (A) for the two physical forms of the API. The higher the ratio, the more 
likely the API can be determined at a given wavenumber. The effective resolution is the inverse 
of the sensitivity-to-noise ratio, which is shown in Figure 3.19 (B). The Raman system was 
demonstrated to be capable of detecting a change of crystalline API of less than 1% w/w across 
the entire wavenumber range.   
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Figure 3.19 A: Signal to noise ratio of the Raman system for different phases of the API; B: Effective resolution for 
the Raman system. 
 
3.3.4.3 XRD System  
The sensitivity of the XRD system was estimated and compared with that of the Raman 
system and the NIR system.  In Figure 3.20 (A), the XRD diffractogram of DIA patches was 
dominated by the strong signal from the polyethylene terephthalate (PET) liners around 20-
30 °2θ.186 The polymer is a semi-crystalline polymer with co-existing crystalline and amorphous 
phases. The signal from the crystalline ibuprofen was overwhelmed by the signal from the PET 
liner. The region of 0 to 20 °2θ was used to calculate the sensitivity of the XRD to API in DIA 
patches (see Figure 3.20 (B)). The diffractograms were corrected by removing a polynomial fit to 
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the baseline. The diffractograms after baseline removal are shown in Figure 3.20 (C). The 
diffraction peaks of ibuprofen crystalline powder were found in the diffractograms of DIA patches. 
 
Figure 3.20 XRD patterns of patch C1, C2 and C3 over A: 0-60 °2θ; B: 0-20 °2θ; C: An overlay of ibuprofen XRD 
pattern and the diffractogram of samples C1-C3 after baseline removal. 
	
The API dissolved in the polymer matrix do not possess the long-range order present in the 
crystalline structure. Thus, the solvated form did not show distinctive Bragg peaks. That is why 
XRD is much more sensitive to the crystalline solids than to the amorphous solids. The sensitivity 
of the XRD system to the crystalline API is illustrated in Figure 3.21 (A). The sensitivity values 
are on the magnitude of a few hundred in detector counts at the diffraction angles unique to the 
crystalline ibuprofen. The noise of the XRD system, however, is on the same magnitude. The noise 
profile of sample C2 is demonstrated in Figure 3.21(B). The large noise compared to the signal 
	87 
	
adversely reduced the limit of detection of the XRD system, for detecting crystalline drug in DIA 
transdermal patches.  
 
Figure 3.21 A: Sensitivity of the XRD system to the crystalline ibuprofen determined from difference spectra of 
samples C1, C2, and C3; B: The standard deviations of diffractograms collected from the sample C2 without 
repositioning.  
The sensitivity to noise ratio is illustrated in Figure 3.22(A) for the crystalline API. The 
shaded regions marked in green color show the major diffraction peaks of crystalline ibuprofen. 
These regions are also associated with relatively high effective resolutions (<1% w/w).  Compared 
to the NIR and Raman systems, the XRD system can only detect the crystalline API at an elevated 
concentration.  
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Figure 3.22 A: A plot of signal to noise ratio of XRD system determined from diffractograms of patches C1-C3; B: 
The effective resolution of the XRD system to the crystalline API. 
Table 3.2 contains all the univariate sensitivities and effective resolutions for the two API 
forms measured by three analytical instruments.  The univariate sensitivity was calculated as the 
sum of the sensitivities across the selected variables (wavelength, wavenumber and 2θ). The 
number of variables included in the calculation potentially affect the results. Therefore, the same 
number of variables (280) were used to calculate univariate sensitivity. Sensitivity across devices 
operating on different principles cannot be compared because different units are involved. Thus, 
the univariate sensitivity was used solely to compare the sensitivity of the two solid phases, via 
the same instrument.  From the results discussed, both NIR and Raman instruments display 
stronger sensitivity to the crystalline phase relative to the solvated phase of the API.  The XRD, 
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on the other hand, exhibited minimal sensitivity to the solvated phase. Alternatively, this means 
XRD exhibited superior selectivity to the crystalline API.  
The effective resolution is a normalized statistic which quantifies sensitivity with respect 
to analytical precision.191 The NIR has the smallest effective resolution for both the crystalline and 
the solvated API. The good sensitivity of NIR system is attributed to the high precision of this 
instrument. However, the NIR system is sensitive to physical variations. The baseline variations 
can easily alter the sensitivity calculation if they are not adjusted properly. 
The Raman system has shown an average effective resolution of 0.69 % w/w. The sample 
homogeneity and repositioning error have direct influences on the noise vector obtained from 
repeated measurements via the Raman probe. The NIR instrument sampled the entire patch and 
the Raman system only sampled about 10% of the patch area due to the small spot size available. 
The impact of sampling heterogeneity was reduced by increasing the number of scans.  
The XRD has the lowest effective resolution of 5.27% w/w. This is because the coated 
patches C1-C3 contain very small amounts of crystalline API that are lower than the detection 
limit of the XRD system. The mass of each coated patch was about 120 mg and the crystalline API 
was only about 1-8 mg. Moreover, the particles were all coated into one thin layer near the liner 
side of the patch. The sample surface may have not been at the best height for optimal signal 
collection. These factors may have contributed to the low XRD signal from the DIA system. From 
the effective resolution results, the two spectroscopic methods (NIR and Raman) have similar or 
better sensitivity as compared to the XRD method for detecting crystalline API in DIA patches.    
 
	90 
	
3.3.5 Instrument Selectivity  
Selectivity is a measure of the performance of an analytical system for detecting or 
quantifying the analyte of interest in the presence of interferences such as excipients, degradants, 
and polymorphs. The selectivity of the NIR instrument to different physical forms of the drug is 
low because the NIR peaks are broad and overlapping. Therefore, calibration and optimization are 
required to achieve good selectivity. The Raman system typically has very good selectivity to the 
different structures of molecules in the solid state. Therefore, it can be used to quantify crystalline 
API in amorphous matrices. Comparatively, the XRD system responds to crystalline materials 
exclusively so it is a technique of good specificity to the crystalline API.  
a. PCA analysis  
 
Figure 3.23PC scores of NIR spectra of samples containing crystalline API (C1-C3) and solvated API (A1-A3) 
	
The confidence ellipses of the two groups representing the samples with and without spiked 
crystalline API are depicted in Figure 3.23 and Figure 3.24. The confidence ellipses included the 
95% confidence interval of the covariance matrices of each sample group. The angle between the 
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planes containing the longer axes is 76.07 ° for NIR and 86.35 ° for Raman, suggesting the variance 
of the data of the two sample systems have limited correlations. The plot showed the potential of 
the NIR system to discriminate spectral variations arising from changes in the crystallinity versus 
that in the solvated API contents.  
 
Figure 3.24 PC scores of Raman spectra of samples containing crystalline API (C1-C3) and solvated API (A1-A3) 
	
Table 3.3 Angles between the longest planes of the 95% confidence ellipsoids fitted to PC scores of C1-C3 and A1-
A3 spectra 
Analytical Method 
Shortest axes of confidence ellipsoids 
Angle (°) 
C1-C3 A1-A3 
NIR x+13.74y+6.37z=0 x-0.25y-1.25z=0 76.08 
Raman x+4.15y+4.99z=0 x-1.58y+0.56z=0 86.35 
 
b. Prediction of the Crystalline API Content in Samples with Solvated API Content Variations 
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Figure 3.25The measured versus the predicted crystalline API contents of patches with varying solvated API 
concentrations using the NIR method. 
 
Figure 3.26 The measured versus the predicted crystalline API contents of patches with varying solvated API 
concentrations using the Raman method. 
An analytical method is selective against a particular interference if the analytical results 
it renders is independent of the variations of the interference.192 The National Committee for 
Clinical Laboratory Standards193 and International Conference on Harmonization194 both 
recommend accessing the degree of interference by measuring the error in the analytical results as 
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a function of the concentration of a given interference. The amorphous form of the drug is an 
interference to the crystalline drug in solid dispersions during spectroscopic analyses.  In the 
current work, the solvated form has high spectral correlations with the crystalline form of drug. 
Therefore, the selectivity of the two analytical techniques to the crystalline drug relative to the 
solvated drug was assessed by the accuracy of the crystalline content predictions in the presence 
of varying solvated API concentrations.  The crystalline contents (1.0 to 8.0 %w/w) of samples 
with different solvated API contents (17.0 to 30.0% w/w) were determined using a PLS model. 
This PLS model was developed from samples of which the solvated API contents were fixed at 
23.5% w/w (samples C1-C3).  
The measured versus the predicted crystalline contents of patches using the NIR model and 
the Raman model are displayed in Figure 3.25 and Figure 3.26. The prediction errors for the tested 
samples containing 17.0%, 23.0% and 31.0% w/w solvated API were 0.54 %, 0.55% and 0.63 % 
w/w using the NIR model, and 0.83%, 0.78% and 0.80% w/w based on the Raman model. The 
smaller RMSEPs of the NIR predictions reinforced the sensitivity results. The NIR instrument 
exhibited superior sensitivity to the crystalline phase of the API. One-way ANOVA suggested 
there was no statistical difference between the predicted crystalline contents across the three 
groups. The PLS models were selective to the crystalline drug with insignificant interference from 
the solvated API. A quantitative XRD method was not developed because the diffraction peaks of 
the drug in DIA patches had low intensity and a long scan time was required (>40 min) to achieve 
sufficient signal. 
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Table 3.4 Prediction errors in crystallinity of samples loaded with different solvated drug content 
Solvated drug content  
(%, w/w) 
RMSEP (%, w/w) 
NIR Raman 
17 0.54 0.83 
23.5 0.55 0.78 
30 0.63 0.80 
ANOVA P = 0.40 P = 0.77 
 
3.4 Conclusions 
A novel way of preparing calibration patches with precisely spiked amounts of crystalline 
API was described. The patch system consists liners coated with crystalline API particles and 
backings cast with solvated API in adhesive polymer. The spiked patches were carefully evaluated 
as the physical properties of the calibration samples must meet several requirements. Specifically, 
the spiked crystalline drug was found to be physically stable over a period of 40 min, which is 
adequate for completing all required analytical characterizations. The Raman analyzer probes an 
area smaller than the area of a patch. To reduce the sampling error, the homogeneity of the 
crystalline particles sprayed on the transdermal patch must be ensured. The sprayed particles 
distributed uniformly across the patch surface. The standard deviations of the area representing the 
crystalline drug is below 10% as determined by an optical microscope.  
The penetration depth of the Raman laser beam in DIA patches was determined.  A PTFE 
film was stacked between DIA patches and the signature peaks of the PTFE decreased in an 
exponential manner. The Raman analyzer was able to detect the signal of PTFE through 8-9 layers 
of transdermal patches. The light penetration depth in the DIA patches was relatively high 
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compared to pharmaceutical powders because a continuous phase of drug and polymer exists in 
the DIA patches. Thus, the Raman system has shown adequate penetration in a single DIA patch.  
Sensitivity and selectivity are important figures of merits. They are commonly used to 
evaluate and compare the performance of analytical methods. The effective resolution is a 
normalized, unitless measure of analytical sensitivity of analytical techniques. It allows direct 
comparisons between orthogonal analytical methods. The NIR and the Raman systems have shown 
lower minimum discernable concentrations for crystalline phases as compared to that for the XRD 
system. The good sensitivity of the NIR system attributes to its low instrumental noise. The two 
potential techniques have also shown superior selectivity to the crystalline API relative to the 
solvated API.  
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Chapter 4 : Development of Quantitative NIR and Raman Methods 
for Crystalline API Content Determination in Drug-in-adhesive 
Patches 
4.1 Background and Introduction 
The sensitivity of the investigated spectroscopic instruments for two API phases have been 
demonstrated in the previous chapter. Quantitative models for crystalline content determination 
via these tools are useful for quality evaluation of DIA patches. The information provided by the 
quantitative models  can be used to study the crystallization mechnisms of an API in a polymer. 
In this chapter, calibration models are developed from spectroscopic analyses of patches spiked 
with crystalline drug, coupled with multivariate regression analyses. The weight percentages of 
the crystalline API in the DIA patches were used as reference values for the calibration. Two 
independent test sets of DIA patches were prepared to evaluate the performance of the calibration 
models. The first test set was composed of spiked samples with a constant total drug content. The 
purpose was simulate the process of solvated drug converting to crystalline drug. The crystalline 
drug and the solvated drug maintained a mass balance during crystallization. The drug load of 
samples of the second test set was the same as the first test set. However,  the samples in this set 
were initially free of crystals. The crystallization of drug in the second test set was continuously 
monitored until the crystalline content reached a plateau. The correlation between the spectra of 
the two sets was calculated and spectral variations were compared. 
Analytical method validation is frequently performed to determine the reliability and 
robustness of the  analytical results. There are two general strategies for conducting method 
validation. The first strategy is to determine specific characteristics of the analytical method and 
to compare them with the acceptance limits. These characteristics typically include specificity, 
accuracy, precision, linearity, limit of detection, and robustness. The second strategy involves 
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using a single concept based on uncertainty to deliver fit-for-purpose evaluation.195 This approach 
focuses on  accuracy profile, a visual tool the method developers use to make statistical decisions. 
The main advantage of the second strategy is that an accuracy profile unifies several traditional 
validation figures of merits.  In this chapter, the validation characteristics as well as accuracy 
profiles were determined to demonstrate the spectroscopic methods are suitable for crystallinity 
quantification in the chosen DIA system.  
 
4.2 Experimental Methods   
4.2.1 Design of Calibration Samples 
The drug ibuprofen and adhesive Duro-Tak® 2052 were dissolved in ethyl acetate and cast 
onto backing layers as described in Section 2.2.2.  Crystalline drug particles were coated onto 
liners following the procedure in Section 3.2.1.2. The backing layers and liners were combined to 
achieve the crystallinity according to a two-factor factorial design (Table 4.1). The two factors 
were the mass fraction of the drug dissolved in the adhesive and the mass fraction of drug sprayed 
onto liners. The crystalline content was varied from 0.0 to 4.8% w/w, or 0.0 to 22.0 % in terms of 
crystallinity (see Table 4.1). Besides a calibration set, two test sets were prepared. Test Set A was 
spiked by 0.0 to 4.8 % of crystalline API. The total API content of each patch was 23.5% w/w. 
The remaining 18.0-28.0 % w/w of the drug was added to the adhesive, maintaining a mass balance 
for the total drug content of these patches. This test set was used to evaluate the performance of 
the calibration model. Test Set B contained 23.5% w/w solvated ibuprofen. The samples of Test 
Set B were stored at 25 °C and 56 %RH. Drug crystallization was periodically measured by the 
NIR and the Raman systems.  
 
Table 4.1 The compositions of calibration and test sets based on a full factorial design 
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 No. 
Crystalline- 
Sprayed API 
(%, w/w) 
Amorphous- 
Solvated API 
(%, w/w) 
Adhesive Dry 
Weight 
(%, w/w) 
Initial 
Crystallinity 
(%) 
 
 
Calibration 
C-1 0.0 17.0 83.0 0.0 
C-2 0.4 17.0 82.6 2.3 
C-3 1.2 17.0 81.8 6.6 
C-4 2.4 17.0 80.6 12.4 
C-5 4.8 17.0 78.2 22.0 
C-6 0.0 23.5 76.5 0.0 
C-7 0.4 23.5 76.1 1.7 
C-8 1.2 23.5 75.3 4.9 
C-9 2.4 23.5 74.1 9.3 
C-10 4.8 23.5 71.7 17.0 
C-11 0.0 30.0 70.0 0.0 
C-12 0.4 30.0 69.6 1.3 
C-13 1.2 30.0 68.8 3.8 
C-14 2.4 30.0 67.6 7.4 
C-15 4.8 30.0 65.2 13.8 
Test A 
(spiked) 
TA-1 0.0 23.5 76.5 0.0 
TA-2 0.4 23.1 76.5 1.7 
TA-3 1.2 22.3 76.5 5.1 
TA-4 2.4 21.1 76.5 10.2 
TA-5 4.8 18.7 76.5 20.4 
Test B 
(recrystallized) TB-1 0.0 23.5 76.5 0.0 
Validation 
(spiked) 
1 0.8 23.5 75.7 3.3 
2 1.2 23.5 75.3 4.9 
3 2.0 23.5 74.5 7.8 
4 3.0 23.5 73.5 11.3 
5 4.0 23.5 72.5 14.5 
	99 
	
Comparisons between Test Set A and Test Set B allows the spectral features between the 
recrystallized and the spiked samples to be compared. The calibration model built from spiked 
samples can only be used to predict crystallinity in DIA patches when strong spectral similarities 
are demonstrated between the spiked and the authentically recrystallized samples. The third 
independent prediction set was a validation set. It was used for calculating the validation 
characteristics (specificity, accuracy, linearity, precision, and multivariate limit of detection) and 
accuracy profile.  All four datasets are summarized in Figure 4.1. Six replicates were prepared at 
each design point. After spectroscopic measurements, the adhesive mixture was dissolved, and the 
drug content in each sample was analyzed by a UV spectrometer (Section 2.2.3.3).  
 
Figure 4.1 A plot of solvated and crystalline drug contents in the calibration set, test sets and validation set. 
 
4.2.2 Spectroscopic Measurements 
The DIA patches were measured by the NIR and the Raman systems within the time frame 
0-tind. The areas of the spiked crystals remain statistically unchanged. The measurement was 
carried out following the procedure described in Section 2.2.4.1.  Each sample was repeatedly 
measured for three times with and without repositioning. Five Raman spectra were collected on 
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each patch: four collected on the corners and one taken in the center. Multiple Raman spectra were 
taken to improve the sampling representativeness because the scale of scrutiny of the Raman probe 
was smaller than the size of one patch (1.5 by 1.5 cm).   The obtained spectra were averaged to 
one spectrum per sample for calibration development and model testing. Due to a heterogeneous 
distribution of crystals in the Test Set B, 16 spectra were measured per sample.  
The spectra of the pure components (blank adhesive films, supercooled liquid and 
crystalline API compacts) were collected on the NIR and Raman spectrometers. A sample of 300 
mg crystalline ibuprofen was compressed at 4000 lb. into a 13 mm tablet using a Carver press 
(3887NE.LAutoPellt, Carver.Inc, Wabash, IN, USA). Approximately 1000 mg of ibuprofen 
powder was melted in a 10 mL beaker at 76 ᵒC and cooled to 25 °C, yielding supercooled liquid 
ibuprofen. Blank adhesive films were prepared by dissolving Duro-Tak® 2052 in ethyl acetate and 
dried in oven at 55 ᵒC for 24 hr.  
 
4.2.3 Multivariate Data Analysis 
4.2.3.1 Development of PLS Models 
Spectral preprocessing and multivariate regression were performed using MATLAB 
R2015 a. (MathWorks Inc., Natick, MA, USA) using the PLS toolbox 7.9 (Eigenvector Research 
Inc., Manson, WA, USA). PLS calibration models were developed from the spectra of the 
calibration samples and the spiked crystalline drug contents expressed in percent crystallinity:  %	ë1ªz∫îrr{s{∫ª = X\]Å… pX…]…ÅÀ 	×100%  (4.1) 
where msprayed is the mass of the drug particles coated on the liners and mtotal is the mass of the drug 
determined by the UV method. Spectral preprocessing and variable selection methods are 
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summarized in Table 4.2. They were chosen by minimization of the root mean squared error of the 
calibration (RMSEC) and cross-validation (RMSECV):   
RMSEC/V = 	 (“®H“®	)DTH∆ 		 (4.2) 
The root mean squared error of the prediction (RMSEP) is calculated as:   
RMSEP = (“®H“®	)DT 	  (4.3) 
where ª:	and ª: are the predicted and the measured crystallinity for the ith sample, n is the number 
of samples for the dataset under consideration, and N is the number of factors used in the model 
construction. Random subsets cross-validation with 6 splits and 20 iterations was used to 
determine the number of latent variables to include in the model. At the optimum number of latent 
variables, RMSEC and RMSECV began to diverge as the latent variable progressively increased.  
Table 4.2 Preprocessing methods and spectral ranges used to build PLS models for crystalline content determination 
in DIA patches 
 NIR data Raman data 
Spectral range 1291-1880 and 2022-2204 nm 767-1225 cm-1 
Preprocessing SNV mean centering 
Weighted least squares baseline removal + 
normalization to unit area + mean centering 
Number of LVd 3 4 
 
																																								 																				
d	LV:	Latent variable 
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4.2.4 Model Comparisons 
The performance of the PLS models based on NIR spectra and Raman spectra were 
compared to determine which instrument is better at predicting crystalline content in DIA system. 
Multivariate limit of detection was calculated for the independent test set and was compared 
sample-wise between the two methods. The prediction ability of the two models were compared 
with respect to accuracy (bias) and precision (standard error of prediction).  
 
4.2.4.1 Multivariate Limit of Detection 
Multivariate detection limit (MDL) is an important figure of merit for characterizing 
instrument performance. The MDL is calculated based on the prediction uncertainty associated 
with all steps of calibration and predictions, and it takes into account the probabilities of 
committing type I (false positive) and type II (false negative) errors:196  ‘’÷ = 	 ∫<H◊,qU ∙ ŸYu + ∫<H⁄,qU ∙ Ÿ“Z¤ p,®                                          (4.5)                                
where ∫<H◊,qU and ∫<H⁄,qU are the single-tailed t-distribution values with probabilities of α and β 
for committing type I and type II errors, respectively. The variable	ŸYu is the standard deviation 
of the estimated detection response 1dof an unknown sample of zero crystallinity. The prediction 
uncertainty was determined using an errors-in-variables approach:197 
Ÿ5“Z¤ p,: 	≈ ℎ™,: + <~\ÅÀ Ÿ›85 + Ÿø8,9«U5 + fi 5Ÿæ85 + Ÿ›™,:5 + fi 5Ÿæ™,:5	          (4.6) 
where ℎ™,: is the leverage of the ith sample in test set, Ç8c¥ is the calibration sample size, fi is the 
estimated regression vector of the multivariate model, and Ÿø8,9«U is the reference uncertainty. For 
calibration samples, the pooled standard deviations of the measurement error and that of the 
prediction residual are denoted by Ÿæ8 and Ÿ›8, respectively. Ÿæ™,: and Ÿ›™,: symbolize the standard 
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deviations of spectral measurement error and the prediction residual for the ith sample in the test 
set. 	The pooled standard deviations of the measurement errors were determined from repeated 
measurements of the samples.  
 
4.2.4.2 Standard Error of Prediction and Bias  
The performances of the multivariate models were evaluated through comparisons of 
standard error of predictions (SEP) and biases between models.198 A t-confidence interval for 
paired samples was used to compare the biases. The difference between the means of the predicted, Ω< −Ω5, has a standard deviation (SD):  
Rq = (q®Hq)D®^flIT×(TH<)  (4.7) 
where a: = G:< − G:5 is the difference between the two errors for the ith sample, and a = q®®^flIT . 
The 95% confidence interval for the true difference in biases is: 
(Ω< − Ω5) ± ∫TH<,t.t5‡	×Rq (4.8) 
The lower and upper limits of a 95% confidence interval for the ratio of the true standard 
deviations are:  
-I-D × <· and -D-I × <·  (4.9) 
where S1 and S2 denote the SEPs of the test set calculated from different multivariate models. Since 
the comparison was based on a common test set, the predictions generated from different 
techniques are often self-correlated.  ÷ is used to account for correlation between the two sets of 
prediction errors:  
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÷ = n + n5 − 10  (4.10)        
                  n = 1 +	5(<H9D);^wD,v.vD‚DTH5   (4.11) 
where r is the correlation coefficient between the two sets of prediction errors and ∫TH5,t.t5‡5  is the 
upper 2.5% point of a t-distribution on n-2 degree of freedom. The two multivariate models were 
considered different when biases or the SEPs were significantly different.  Two models were not 
significantly different only when the confidence interval for the true difference in biases included 
0 and the ratio of SEPs included 1.   
 
4.2.5 Comparison of Spiked and Recrystallized Patches 
The spectra of spiked samples (Test set A) and naturally recrystallized samples (Test set 
B) were paired up and compared based on the predicted crystalline contents. For example, a 
spectrum of a spiked sample with 2.0% predicted crystallinity was obtained. At the same time, a 
spectrum of a recrystallized sample with 2.0% predicted crystallinity was also obtained. The 
correlation coefficient between the two spectra was calculated and the significance was tested by 
a t-test (P=0.05).  The variance of the spectral signal was compared by using PC scores and the 
multivariate diagnostics including Hotelling’s T2 and Q residual.  
 
4.2.6 Validation  
The objective of validation is to ensure that every future measurement in routine analysis 
will be close enough to the unknown true value.199 The study combines a number of validation 
approaches such as accuracy profile195 and ICH validation strategies. The approach used in this 
study consisted of checking the conformity of performance measures to acceptability limits. 
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Method validation, together with uncertainty assessment, provide a way to independently and 
reliably assess the quality of analytical results.  
 
 4.2.6.1 Specificity 
According to USP <1119>, evaluations of the specificity of a NIR method to the analyte 
of interest is based on both spectral attributes and chemometric parameters.197 This approach is 
optional for other spectroscopic techniques such as Raman spectroscopy. All pure components 
were measured by the chosen analytical systems. The correlation coefficients between the loadings 
of the calibration model and the spectra of the pure components were used to evaluate the method 
specificity.  
 
4.2.6.2 Precision 
Precision describes the closeness of multiple measurements of the same homogeneous 
sample under a prescribed condition. Repeated measurements of the validation samples at Q3.3%, 
7.8% 11.3% and 14.5% crystallinity were performed. Repeatability with no repositioning was 
determined as the relative standard deviations of six readings, without changing the location of 
each sample relative to the detector. Repeatability with repositioning was performed on patches 
that underwent removal and replacement on the sampling stage between consecutive scans. 
Intermediate precision was conducted on validation samples prepared on three different days.  
 
4.2.6.3 Accuracy Profile  
Accuracy profile is a decision-making graphical tool designed to help analysts decide 
whether or not an analytical procedure is valid.195 The difference between the measured value (}) 
and the unknown true value (µ) should be lower than an acceptance limit (x): 
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} − µ < x  (4.12) 
The probability that a measurement will fall outside the acceptance limits is less or equal 
to the maximum risk (5%) that the analyst is able to take during routine use:  √1( } − µT < x) ≥ Á  (4.13) 
The Á-expectantion tolerance interval is calculated based on the following formula to 
check if it fits into the acceptability limits:200-201  ùË ± Ö;È•ŸË  (4.14) 
where  σË5 = σÎ5 + σÏ5  (4.15) σË5 , σÎ5  and σÏ5  are the estimates of the intermediate precision variance, the between-day variance 
and the within-day variance. ùË  is the estimated bias. 	Ö;  is the Á quantile of the Student’s t-
distribution with Ì degree of freedom: ú = (†Ä<)D†Ä I^ D/(™H<)Ä(<H I^ )/™T  (4.16) 
Ó = 	 Ô≥DÔ≤D  (4.17) 
where p is the number of experimental conditions used in precision tests and n is the number of 
independent replicate in each series. È• is an expasion factor that takes into account the variability 
of the mean bias. It was estimated as follows: 
È• = 1 + <™T∂D   (4.17) 
with 
          = †Ä<T†Ä<  (4.18) 
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4.3 Results and Discussion 
4.3.1 Calibration Model Development 
The increase in opacity of patches (Batch C6 to C10) because of increasing crystalline 
content is illustrated in Figure 4.2. The crystallinity from left to right are 0, 1.7, 4.9, 9.3 and 17.0%, 
corresponding to mass fraction of 0, 0.4, 1.2, 2.4 and 4.8% w/w of film weight. The coated particles 
were uniformly distributed across the patch surface.   
 
Figure 4.2 Calibration samples spiked by crystalline ibuprofen particles. The crystallinity from left to right are 0, 
1.7, 4.9, 9.3 and 17.0%, corresponding to mass fraction of 0, 0.4, 1.2, 2.4 and 4.8% w/w. 
 
4.3.1.1 NIR PLS Model  
 
Figure 4.3 A: NIR spectra of the calibration set with varying crystalline content; B: SNV preprocessed NIR spectra 
of the calibration set in the region of 1560-2250 nm. 
The dependence of NIR signal intensity on crystalline drug is illustrated in the Figure 4.3. 
Each spectrum represents the mean of six spectra at each crystalline level (Batch C6-C10). There 
is a baseline change accompanying the change in the crystalline content.  The baseline first 
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increased as the crystallinity increased from 0% to 4.9% and then decreased as the crystallinity 
continued to increase. SNV was applied to the NIR spectra to reduce the influence of baseline and 
scale differences. The SNV-corrected spectra are drawn in Figure 4.3 (B). Although there is a 
decreased baseline near 2000 nm, there is a pronounced increase in the peak intensity at 2171 nm 
with the increase of the crystalline content. Spectral differences between pure crystalline and 
supercooled liquid phases was observed in this region.  
 
Figure 4.4 A: RMSEC and RMSECV as a function of number of latent variables used in the NIR PLS model 
development. B: PC scores of the calibration set and the test set A. 
A PLS model was developed from the NIR spectra of the calibration set. The wavelength 
regions of 1291-1880 and 2022-2204 nm were selected.  The wavelength regions of 1400-1500 
nm and1880-2022 nm were excluded because they were affected by moisture. The spectral 
preprocessing, including SNV and mean-centering, were performed after wavelength selection.  
Three latent variables were chosen based on the divergence of RMSEC and RMSECV as a function 
of latent variable, as is shown in Figure 4.4(A). One may argue that five latent variables should be 
selected. However, the first three latent variables explained more than 95% variance in both X and 
Y. Adding additional latent variables may run the risk of overfitting the model. The variance in X 
(NIR signal) accounted by the three LVs were 85.83%, 9.99% and 2.11% whereas the variance in 
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Y (crystallinity) explained by the three LVs were 94.48%, 1.14% and 0.87%. The PC scores of 
calibration data on LV1 and LV2 were plotted in Figure 4.4(B). The scores on LV1 gradually 
increased as the crystalline content increased. The variance spanned by the test set is contained in 
that of the calibration set, as is shown in Figure 4.4(B).  
 
4.3.1.2 Raman PLS Model  
 
Figure 4.5 The preprocessed Raman spectra of calibration set with varying crystalline content (preprocessing 
methods include weighted-least-squares baseline removal and normalization to unit area). 
Each spectrum in Figure 4.5 is the mean of spectra of samples at each crystalline level. 
Several spectral changes were observed as the crystalline content was increased. Peak intensity 
increased at 1207, 958, 833 and 746 cm-1. Two shoulder peaks emerged at 820 and 784 cm-1. 
Wavenumber of the peak at 1185 and 998 cm-1 changed with the increase in crystallinity, which is 
consistent with the peak changes found between the supercooled liquid and the crystalline drug.  
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Figure 4.6 A: RMSEC and RMSECV as a function of number of latent variables used in the Raman PLS model 
development. B: PC scores of the calibration set and the test set. 
The wavelength regions of 767-1225 cm-1 were selected to develop a PLS model.  This 
region is inside the fingerprint region of organic molecules thus providing plentiful of information 
about the structure and arrangements of the drug molecules.   The spectral preprocessing methods 
include weighted-least-squares baseline removal, normalization to unit area and mean-centering. 
The number of latent variables (4 LVs) were chosen based on the divergence of RMSEC and 
RMSECV as a function of latent variable number, as is shown in Figure 4.6 (A).  The variance in 
X (Raman signal) accounted by the first four LVs were 74.24%, 15.10%, 6.57% and 2.21% 
whereas the variance in Y(crystallinity) explained were 61.20%, 17.11%, 6.74 and 8.16%. The 
scores of calibration data on LV1 and LV2 were plotted in Figure 4.6(B). The variance spanned 
by the test set is contained in that of the calibration set. 
 
4.3.1.3 Model Performance Evaluation 
The PLS models were calculated and optimized using the NIR and the Raman spectra. The 
model statistical parameters are displayed in Figure 4.7. From the calibration and prediction errors, 
the NIR model outperformed the Raman model. The calibration and prediction errors of the NIR 
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method are approximately 50% lower than that of the Raman method. The agrees with the results 
of the sensitivity study in 3.3.4 in which NIR instrument showed better sensitivity to the crystalline 
API relative to the Raman instrument.  
 
Figure 4.7 The predicted and measured crystalline contents of the calibration, test and validation sets. A: NIR data; 
B: Raman data. 
The predictive ability of the two models were compared in terms of SEP and bias. The 
confidence interval of the bias was estimated to be (-1.422, 1.724), suggesting the bias was not 
significant between the two models. However, the confidence interval of the SEP, (0.318, 0.690), 
did not include 1. The SEPs of the prediction results for the NIR is smaller than that of the Raman. 
This result confirms that the NIR analyzer exhibits superior precision. 
 
4.3.2 Test Sets - Comparing Spiked and Recrystallized Patches 
The similarity between the spiked and the recrystallized patches was evaluated using the 
Raman method. The set A was prepared by spiking crystalline API and solvated drug to achieve a 
total drug content of 23.5% w/w. This is to simulate the natural drug crystallization process which 
follows the direction pointed out by the black arrow drawn in Figure 4.8. Test set B consisted 23.5% 
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w/w API in the solvated form. As the patches were stored in stressed environment to induce 
crystallization, the crystalline content started to increase and eventually reaching similar 
composition as the spiked samples. Five pairs of samples with similar predicted crystallinity were 
grouped together for comparisons. 
 
Figure 4.8 The crystalline drug contents and solvated drug contents of spiked and recrystallized DIA patches.  
Samples marked in orange rectangles are the five pairs of samples compared in 4.3.2. 
A high degree of spectral correlation was found between the two test sets as the crystallinity 
was varied between 0.3 and 5.0% w/w, as is shown in Figure 4.9. The preprocessing method, 
normalization to unit area, helped to remove the scale variation. The increase in the crystallinity 
can be well tracked in Raman spectra in both the spiked and the recrystallized samples. There were 
increases of peaks at 708, 1144 and 1058 cm-1. Two shoulder peaks emerged at 1107 and 1170 cm-
1 as the crystallinity reached 10, or 2.5% w/w.  The spectral similarity was represented by the high 
correlation coefficient (>0.98) between each pairs of spectra.   
The PC1 and PC2 scores of the two test sets were plotted in Figure 4.10 (A). The first two PCs 
(90% variance in X) represent where the variance of the samples reside with respect to the 
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calibration data. Both the spiked and recrystallized patches were found within the space enclosed 
by the calibration samples. The Hotelling’s T2 and Q residuals of the two sets can be found in 
Figure 4.10 (B). The recrystallized samples yielded larger Q residuals than that of the spiked 
samples, indicating presence of unmodeled variance. Figure 4.9 shows the correlation between the 
spectra of the spiked and the recrystallized samples decreased progressively as the crystalline 
content increased. The crystals tend to recrystallize at the interface between the liner and the 
adhesive layer. The interface can serve as heterogeneous nucleation sites. With this knowledge, 
the test set B was spiked with drug crystals on the same interface.  
A possible explanation for the inflated Q-residuals of the naturally recrystallized samples 
is the shape and sizes of crystals in this system is different from the spiked samples.  Another 
possible explanation is the water contents of the samples were different. The intensity of 
fluorescence measured by the Raman spectrometer can be quenched by water.202 Factors altering 
the baseline or fluorescence level of the Raman spectra may have inflated the Q-residuals of the 
recrystallized samples.  
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Figure 4.9 Raman spectra of spiked and recrystallized patches with similar crystallinity (0.5 to 20% in crystallinity 
or 0.3 to 5% w/w). The correlation coefficient (r) for each pair of spectra can be found in each plot. 
	
Figure 4.10 A:  A schematic demonstrating similar PC scores of the five groups of recrystallized and spiked 
samples. Samples marked in red circles are the five pairs of samples compared in terms of spectral similarities in 
4.3.2.B: Hotelling’s T2 and Q residuals of the calibration set and two test sets.  
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Figure 4.11 Q-residual contribution plots for the calibration set and two test sets.   
 
4.3.3 Validation Results 
4.3.3.1 Specificity  
The spectral similarity and differences of NIR and Raman spectra of pure components are 
displayed in Figure 4.11 (A) and Figure 4.12 (A). The plots were scaled (normalization to unit 
area) to facilitate visual comparisons. The correlation between components are calculated for the 
full wavelength or wavenumber region as well as for the region used in the calibration models. 
The NIR spectrum of drug in the crystalline form resembles that of the supercooled liquid form. 
The NIR spectra of these two physical forms had high correlation (0.96).  In comparison, 
crystalline and supercooled liquid ibuprofen show many differences in Raman spectra. A 
correlation coefficient of 0.81 was observed between their spectra. The crystalline ibuprofen has 
peaks at 663, 784, 820 cm-1 that are absent in the Raman spectrum of the supercooled liquid. The 
crystalline ibuprofen also has larger peaks compared to the supercooled liquid.  
In Table 4.3, The correlation between the API and the adhesive is higher for the NIR spectra 
than that for the Raman spectra. This finding supports literature reports that Raman spectroscopy 
is sensitive to conjugated double bonds, aromatic rings and other structures present in most APIs, 
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but is not sensitive to polymeric excipients,203-204 which may be related to the high chemical 
specificity of this technique. 
Table 4.3 Correlation coefficients between the components used in the DIA patch formulation  
Correlation coefficient 
NIR Raman 
1100-2500 
nm 
860-1108 
2020-2209 nm 
150-1850 
cm-1 
767-1225 
cm-1 
API(crystal) vs. API(supercooled liquid) 0.96 0.99 0.81 0.79 
API(crystal) vs. Adhesive + liner + backing 0.89 0.87 0.09 -0.14 
API(supercooled liquid) vs. Adhesive + 
liner + backing 0.85 0.87 0.08 -0.13 
 
 
Figure 4.12 A: NIR spectra of pure components of DIA patches; B: An overlay of the first two loadings of the NIR 
PLS model and preprocessed NIR spectra of pure components of DIA patches. Plots were scaled to allow visual 
comparison. 
 
The specificity of the developed methods was evaluated by comparing the loadings and the 
spectra of the pure components. The loading of the first PC of the Raman model exhibited the 
highest correlation with the spectrum of the crystalline API, whereas the second loading of the 
NIR model showed some overlaps with both API forms.  
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Figure 4.13 A: Raman spectra of DIA components; B: An overlay of the first two loadings of the Raman PLS model 
with preprocessed Raman spectra of pure components of DIA patches. 
 
4.3.3.2 Precision  
Precision describes the “closeness of agreement between a series of measurements obtained 
from multiple sampling of the same homogeneous sample under the prescribed conditions”.194 It 
is defined at three levels by the ICH Q2: repeatability, intermediate precision and reproducibility. 
Repeatability expresses the precision under the same operating conditions over a short interval of 
time. Repeatability is required for validation of assay methods. Intermediate precision considers 
variations within-laboratories: different days, different analysts and different equipments, etc. The 
extent to which intermediate precision is established is based on circumstances under which the 
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procedure is intended to be used. Reproducibility expresses the precision between laboratories. It 
is not necessary to test reproducibility if all analyses are accomplished in one laboratory. 
Table 4.4 Precision results of the quantitative methods for crystalline content quantification 
Method NIR Raman 
Crystallinity (%) 3.3 7.8 11.3 14.5 3.3 7.8 11.3 14.5 
w/o repositioning (%) 0.10 0.12 0.09 0.15 0.14 0.15 0.11 0.39 
repositioning (%) 0.16 0.26 0.32 0.24 0.26 0.37 0.54 0.68 
intermediate (%) 0.14 0.33 0.37 0.48 0.47 0.51 0.57 0.87 
 
The results of the repeatability and reproducibility of the two quantitative methods are 
summarized in Table 4.3. Precision was determined with patches of four crystallinity levels (3.3, 
7.8, 11.3 and 14.5%) of the validation set. Except for the patches scanned with repositioning at the 
lowest crystallinity level (3.3%) via Raman, all three levels of the validation samples exhibited 
relative standard deviations smaller than 5.0%, representing consistent performance of the two 
analytical systems. It was noted that repositioning was the major contributor to precision error for 
Raman spectroscopy.  As the laser spot size (1.5 mm) of the Raman analyzer is smaller than the 
size of the patch (15 mm), this error may be due to intra-patch heterogeneity. Intermediate 
precision was performed on three different days. The pooled standard deviation (SD) for samples 
scanned with repositioning on day one (0.31% for NIR and 0.60% for Raman) was similar to what 
were observed on a different day (0.33% for NIR and 0.67% for Raman). 
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4.3.3.3 Accuracy Profile 
	
Figure 4.14 Accuracy profile for A: NIR method; B: Raman method. 
	
The β tolerance intervals calculated with the NIR and the Raman methods are shown in 
Figure 4.13.  The central solid line of Figure 4.13(A) represents the mean biases of NIR predicted 
crystallinity at five validation concentrations. The β tolerance interval was calculated from the 
relative standard deviations of the intermediate precision and it was normalized to the mean 
crystalline content. That explained why the width of the β intervals was the largest at the lowest 
crystalline content level. For both methods (NIR and Raman), the β intervals were contained within 
10% at the crystalline content levels (3 to 22%) under evaluation, indicating the lower level of 
quantification is below 3.0%. However, this is only true when the bias is small (<5%). Two 
extrapolated lines from the lowest concentration of the validation set to 0% crystallinity were 
drawn to determine the concentrations at which the β interval exceeded ± 10%. Thus, the 
intersection between the accuracy profile and the acceptance limits defined the lower level of the 
dynamic range of the quantitative method. The lower level of the dynamic range of the Raman 
method was about 3.0% while it was not defined for NIR because the accuracy profile was 
confined in the 95% acceptance limits even at 0% crystallinity.  
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4.3.3.4 Multivariate Detection Limit 
The multivariate detection limit (MDL) was calculated to facilitate model optimization and 
evaluation. The method is based on statistical analysis and error propagation. The MDL 
dependents on the accuracy of the reference method, instrumental noise, spectral interference and 
modeling error. The sources of error for the developed analytical methods are summarized in table 
4.4. The reference method used in this study was a digital balance, its reference error was 
negligible. Spectral interference constituted less than 0.1% of the total prediction uncertainty. 
Comparatively, prediction residuals and calibration or model errors account for most of the 
prediction uncertainties.  
Table 4.5 Sources of errors for the developed analytical methods.  
Instrument Sources of errors 
Modeling error Prediction error 
Variance- 
cal. set 
Reference 
error 
Spectral 
error-cal. 
set 
Spectral 
error-test set 
Prediction 
residual-
test set 
NIR 
Variance 0.198 0.006 1.42×10-6 1.65×10-5 1.53 
Percentage (%) 11.42 0.35 <0.001 <0.001 88.23 
Raman 
Variance 0.641 0.009 2.12×10-4 2.99×10-4 2.24 
Percentage (%) 22.18 0.31 <0.001 <0.001 77.51 
	121 
	
 
Figure 4.15 Multivariate detection limit of the test set samples based on A: the NIR method; B: the Raman method. 
	
Multivariate detection limits determined from Equation (4.5) are sample specific because 
the calculation was performed with the information of each sample. Each sample has a leverage 
that increases with the concentration of the analyte. That is why the MDLs demonstrated in the 
Figure 4.14 are slightly greater for samples with high crystalline contents than those with low 
crystalline content. The dotted lines in Figure 4.14 (A) and (B) represent the cutoff values at which 
the predicted crystalline contents are equal to the MDLs, based on predefined type I and type II 
errors. The confidence of correctly predicted the crystallinity of samples found below this line is 
lower than the predefined confidence limit(s).  
The MDLs estimated in this way were recorded in Table 4.5, along with the detection limits 
determined from IUPAC definition. The mean value of the MDLs of validation samples was used 
to represent the overall MDL. As the conventional LOD is defined as the lowest concentration of 
an analyte that can be distinguished from the blank, the LOD based on IUPAC was much smaller 
than the MDL. Using the LOD from IUPAC, the probability of stating there is no crystalline API 
in a patch which contains crystalline drug is low. In Figure 4.15, all samples spiked with crystalline 
API are observed above the LOD. However, the LOD was insufficient to reject blank samples. 
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The predicted concentrations of blank samples are greater than the LOD. Therefore, the error of 
detecting crystallinity in blank samples is high (high type I error). The blank samples can be 
distinguished from the crystalline drug-bearing samples given MDLs, suggesting MDL is a more 
stringent metric compared to the LOD.   
The calculated MDLs enable direct comparisons of MDLs between different analytical 
instruments and modeling methods. Overall, the NIR method has lower detection limits compared 
to the Raman method. Based on the MDL at 5% of both α and β, the MDL for NIR is 2.67 or 0.63% 
w/w and 3.61 or 0.85% w/w for Raman. The NIR method can detect 10% drug recrystallization in 
a patch loaded with as little as 6.3% w/w drug; while the Raman method detects the same 
conversion percentage only when the drug concentration is greater than 8.5% w/w.   
Table 4.6 Detection limits of NIR and Raman methods for crystalline content quantification of the API in DIA 
patches.  
Detection Limit (%) NIR Raman 
MDL (α = β = 0.10) 2.08 2.81 
MDL (α = β = 0.05) 2.67 3.61 
LOD (IUPAC, α = 0.05)  0.53 0.96 
 
Figure 4.16 Comparisons of the predicted crystalline contents to MDL and LOD. A: The NIR method; B: The 
Raman method. 
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4.4 Conclusions  
The aim of the study was to develop and validate analytical methods for the quantification 
of crystalline contents of the API in DIA patches. This study utilized a backscatter Raman 
spectrometer and a NIR spectrometer. The calibration models were developed from NIR and 
Raman spectra of patches spiked with crystalline drug according to a sample design that minimize 
the corrlation between the two physical forms of the API. The weight percentages of the crystaline 
drug spiked in the DIA patches were used as reference values. Two independent tests sets were 
prepared to verify the quantitave capability of the PLS models. The first test set was composed of 
spiked samples with a constant drug mass in order to keep a mass balance between the crystallized 
and solvated drug forms. The second test set contained the same drug concentrations as the first 
test set; while the samples in this set were initially free of spiked crystals. The crystallization in 
the second test set was continuously monitored until the crystalline contents reached a plateau. 
Strong  correlations between the spectra of the two sets was found, showing the spectra of patches 
made by spiking crystals and from natural crystallization were very similar. Therefore, the spiking 
method was used to prepare validation samples.  
The developed methods were validated using the fit-for-purpose concept. Accuracy profiles derived 
from biases and intermediate precisions related the method performance to the predefined acceptance 
criteria. The b-intervals constructed from the NIR and the Raman methods were contained in a predefined 
acceptability interval (±10 % crystallinity) across the three levels of concentration covering the validation 
domain. The prediction uncertainty of the method was calculated using an independent data set to yield 
sample-specific multivariate detection limits (MDL). The overall MDL of the Raman method is about 3.61% 
and the MDL of the NIR method is 2.67%, with a 5% type I and type II errors. Finally, the variance of the 
spectral signal was compared between the spiked and the naturally recrystallized samples using PC scores 
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and the diagnostic measures (Hotelling’s T2 and Q-residuals). Strong correlations between the Raman 
signals of the two systems were identified.  
Development of reliable solid-state quantification methods is a critical component in 
understanding crystallization processes. The approach demonstrated in this chapter can be applied 
to develop analytical methods for physical stability studies. In this case, sample representativeness, 
analytical capability and method suitability were integrated to form a systematic approach for 
crystallization quantification. The developed approach enabled reliable predictions of crystalline 
drug content in DIA transdermal patches.  
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Chapter 5 : Monitoring Crystallization of Ibuprofen in 
Supersaturated Ibuprofen Duro-Tak ®2052 Transdermal Patches 
	
5.1 Background and Introduction 
Supersaturated transdermal drug delivery systems have been utilized to improve the 
delivery of drugs through the skin. The unique advantage of supersaturated systems is that drug 
supersaturation provides an increased thermodynamic activity and thus improved skin permeation. 
However, DIA patches supersaturated with active pharmaceutical ingredients are 
thermodynamically unstable and are prone to recrystallization. Physical instability is the major 
hurdle that limits the application of supersaturation in transdermal drug delivery. 205 It is essential 
to understand the drug crystallization processes from the adhesive systems to enhance the physical 
stability of such systems. The objective of this chapter was to determine the crystallization kinetics 
of drug from a DIA system via vibrational spectroscopy. The information generated was used to 
understand the factors that affect the extent of drug crystallization.  
Crystallization of ibuprofen in supersaturated Ibuprofen Duro-Tak® 2052 polyacrylate 
pressure sensitive adhesive patches was monitored by Raman spectroscopy.  The crystallinity 
estimated from a PLS model was fitted by a Weibull function to determine the recrystallization 
kinetics. The degree of supersaturation was determined based on the saturation solubility of the 
API in the adhesive, considering the influence of environmental humidity. The risk of 
environmental factors was discussed on the basis of crystallization of APIs in DIA patches. 
   
	126 
	
5.2 Experimental Methods  
5.2.1 Materials and Storage Conditions 
Transdermal patches for stability evaluation were prepared according to the target 
formulation (Section 2.2.1) and they were stored in desiccators with changing temperature (5, 25 
and 45 °C) and humidity (11, 32 and 56 %RH). Saturated solutions of lithium chloride, magnesium 
chloride and magnesium nitrate were used to maintain corresponding relative humidifies. Patches 
were withdrawn from the stability chambers to collect Raman spectra at various sampling time 
points until the crystalline contents reached plateaus. Prior to spectroscopic measurements, the 
samples were equilibrated in a chamber with controlled temperature (25 °C) and humidity 
(56 %RH) for 30 min. 
Table 5.1 Storage conditions used in the stability evaluation 
Experimental condition Humidity (% RH) Temperature (°C) 
1 32 ± 5 5 ± 2 
2 11 ± 5 25 ± 2 
3 32 ± 5 25 ± 2 
4 56 ± 5 25 ± 2 
5 32 ± 5 45 ± 2 
 
5.2.2 Determination of Recrystallization Kinetics  
The effects of temperature and relative humidity on the rate of crystallization was 
investigated. In Chapter 2, the patches showed preferential nucleation along the edges and at the 
interface between the liner and the adhesive. These observations suggest the nucleation is primarily 
heterogeneous, rather than homogenous. Avrami equation assumes homogeneous nucleation 
occurring randomly throughout the entire sample. Therefore, Avrami equation is not an 
	127 
	
appropriate model to describe the kinetics of recrystallization in the DIA system. An assumption 
free, numerical function was selected to correlate model parameters to the rate of crystallization. 
The crystalline content determined from the Raman PLS model (Section 4.3.1.2) was fitted into a 
Weibull function: 
} ∫ = 1 − eH(…Å)Ò  (5.1) 
where } ∫  is the relative crystallinity determined by dividing the crystallinity at each time point 
by the final crystallinity. a is the scale parameter and b is the shape parameter. At each level of 
relative humidity, the crystallinity determined from the Raman method were fitted in equation 
(5.1).  The values of a and b were optimized by an unconstrained non-linear fitting method using 
MATLAB R2015a. The correlation coefficient, r2, was utilized to determine the fit of the data to 
the Weibull function. Two parameters were used to analyze the crystallization rates at different 
humidty conditions. The half-crystallization time, t50, was interpolated from the fitted curve. It 
represents the time at which the crystallization is half of the total relative crystallinity. The 
parameter 1/t50  was plotted as a function of the relative humdity emploeyd. The other parameter, }«Tq, denotes the percent crystallinity at the last time point and was used to represent the extent 
of drug crystallization at the end of the stability study.  
 
5.2.3 Impact of Humidity on Drug Crystallization  
The dependence of drug crystallization on humidity was determined by regressing the 
crystallization rate constant k with the RH%. After the crystallinity reached plateau, the solvated 
drug contents in the adhesive was used to determine the apparent solubility (ë•	 ) for each 
temperature and humidity combination. The solubilities of API at humidity between 11 % RH and 
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56% RH were estimated by a linear interpolation. Therefore, the degree of supersaturation (S) of 
ibuprofen in the ibuprofen Duro-Tak® system can be calculated according to:   
R = 	 æ…]…ÅÀHæ\Y£	   (5.4) 
and  
ë• 	= 	 æ…]…ÅÀHæ ^p	æ…]…ÅÀ   (5.5) 
where };S;c¥  is the API content determined by UV analysis,  }8  is the crystalline content 
detemrined from the Raman method, and }«Tq is the crystalline content at the end of stability study.  
A solid dispersion system with a degree of supersaturation smaller than 1 was considered to be 
thermodynamically stable whereas a degree of supersaturation greater than 1 is indicative of a 
physically unstable system under a cetain termperature and humdity. The plot of degree of 
supersaturation of the API in the DIA system can help to guide the selection of storage conditions 
for DIA patches. 
 
5.3 Results and Discussion 
5.3.1 Predicting Crystalline Contents of Samples Stored Under Stress Conditions 
Ibuprofen was fully dissolved in the adhesive upon preparation.  Only one  crystalline phase 
(phase I) was expected because the storage conditions involved in the study were extremely 
unfavorable for polymorphic form II, which was identified after rapid quench of the melt at least 
60 °C  below the Tg of ibuprofen(-48 °C).206 Any change in physical form, including crystal 
morphologies and density, may lead to changes in the spectroscopic responses. The spectroscopic 
variations unrelated with crystallinity were minimized with spectral preprocessing and variable 
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selection. From Chapter 5, the stability samples had very similar spectroscopic responses as that 
of the spiked samples. Therefore, the PLS models were used to predict the crystalline contents of 
naturally recrystallized patches. 
 
Figure 5.1 Raman spectra of samples used in the stability study. 
The Raman spectra of samples stored for 80 days were plotted in the Figure 5.1. A 
progressive increase of the baseline was found. This may be related with changes of the sample 
systems, such as density changes and sorption of water. spectrometer drifts is also possible over 
this period of time. The baseline variation was removed by weighted least squares baseline removal 
and normalization to unit area. The crystalline contents were estimated using the developed Raman 
PLS model. The predicted crystalline contents at five humidity and humidity conditions are 
displayed in Figure 5.2.  
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Figure 5.2 Crystalline contents of API in samples used in the stability study. The error bars represent the standard 
deviation of five replicates. 
 
Figure 5.3 A: Scores of the first two latent variables of the Raman PLS model; B: Hotelling’s T2 and Q-residuals of 
the calibration set, and the stability set. 
	
Diagnostics, including Q-residuals and Hotelling’s T2, were used to determine if the 
models developed in the Chapter 4 span the variability of the stability samples. They also represent 
how models react to changes in input variability. The diagnostics of the majorities of the stability 
samples are contained within the 95% confidence intervals of the calibration set (Figure 5.3(B)). 
The stability samples, denoted by purple triangles, showed high Hotelling’s T2 and Q-residuals. 
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High Hotelling’s T2 indicates that the modeled variability has exceeded the calibration range.  The 
calibration range was 0.0 - 28.0% in crystallinity while the crystalline contents of these samples 
were predicted to be higher than 30.0%. Four samples with low Hotelling’s T2 but high Q-residuals 
were marked by yellow pentagons. Although their corresponding scores are found within that of 
the calibration set, as is shown in Figure 5.3(A), the high Q-residuals may be associated with the 
spectral variations demonstrated in Figure 5.4. 
The plot of diagnostics revealed there were unexpected variations detected by the Raman 
analyzer. The variations can result from sample density changes, instrument drift or measurement 
inconsistency.  A part of the stability samples can be used to augment the calibration to span the 
variabilities of the calibration; alternatively, calibration samples can be stored in varying 
environmental conditions to incorporate the variability of temperature and humidity into the 
models. 
 
Figure 5.4 A: Preprocessed Raman spectra of calibration samples, samples for stability testing and samples with 
high Q-residuals. Preprocessing methods include weighted least squares baseline removal and normalization. B: An 
overlay of the mean of calibration spectra, the mean of high Q-residual sample spectra and Q-contribution plot.  
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5.3.2 Effect of Temperature on Physical Stability of the DIA System 
The temperature and humidity had influences on both the extent and the rate of 
crystallization. The rate of crystallization first increased with temperature from 5 °C to 25 °C. 
However, as temperature further increased from 25 °C to 45 °C, a drop in the overall crystalline 
content with temperature was observed. The films stored at 45 °C had reached an equilibrium at 
around 2-3 month, as the crystallinity stayed unaltered afterwards. The crystallization kinetics are 
fast at such an elevated temperate (100 °C above the Tg of the system). Conversely, the patches 
stored at 5 °C may not have reached the equilibrium as crystallization is considerably slower with 
a temperature drop of 40 °C. A photo of the stability samples taken at the end of five months is 
shown in Figure 5.5. It demonstrated numbers and sizes of drug crystals of samples stored at 5 °C 
and 45 °C are lower than that of samples preserved at 25 °C. 
 
Figure 5.5 A photo of DIA patches prepared with 23.5 % w/w API and 76.5% w/w adhesive. The photo was taken at 
the end of a 6-month storage. Each row of sample corresponds to one of five storage conditions. 
The observed phenomenon can be explained by considering kinetic and thermodynamic 
factors affecting crystallization. Kinetically, the molecular mobility increases with temperature. 
Both the nucleation and crystal growth rates increase with temperature. Thermodynamically, the 
crystallization is under complex influences of the degree of undercooling and supersaturation. 
Raising the temperature would lower the degree of undercooling but increase the solubility of API 
in the polymer. That is why the maximum crystallization rate is usually observed between the glass 
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transition temperature and the melting temperature. However, the crystallization does not follow 
Arrhenius relationship because of the wide temperature range used in the study.   
 
5.3.3 Effect of Humidity on Physical Stability of the DIA System 
An increase of crystallinity was observed in Figure 5.2 at higher humidity levels. The 
crystallinity at each time point was transformed to relative fractions, based on the crystallinities at 
the last time point. The crystallization profile was fit into a numerical function (Weibull) to 
understand the kinetics of drug recrystallization. The R2 and t50 from the curve fitting are recorded 
in Table 5.2.  
Table 5.2 Parameters calculated from curve fitting using a Weibull function 
 b a R2 t50 Xend 
25 °C 56%RH 2.09 59.86 0.993 49.2 37.9 
25 °C 32%RH 2.58 62.50 0.998 52.5 22.7 
25 °C 11%RH 2.37 64.70 0.999 54.5 16.8 
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Figure 5.6 Crystallinity as a function of time for DIA patches (23.5%w/w API and 76.5%w/w adhesive) stored at 
25 °C and three relative humidity conditions (56 %RH, 32 %RH and 11 %RH). 
The rate of crystallization changed linearly with the relative humidity. This is demonstrated 
by plotting 1/t50 as a function of relative humidity (see Figure 5.7). There are many theories that 
explain why environmental water leads to faster crystallization. Hancock, Zografi and Marsac 
described the phenomenon as a result of water-induced plasticization and ensuing enhanced 
molecular mobility. 122, 207  
Crowley and Zografi proposed that the absorbed water decreases the API solubility in the 
polymer by competing with the API to bind with the polymer at the hydrogen bonding sites. This 
changes the equilibrium between the bound API and the free API, resulting in an increase in the 
API that are free to form crystals.208-210 The process is demonstrated in Figure 5.8. Chenevas-Paule 
proposed that incorporation of drug molecules in the acrylate polymers leads to breakage of 
intramolecular H-bonds between polymer chains of the adhesive.210 The interaction between drug-
acrylic polymers further increased the number of water-binding sites. This process promotes to 
drug release and is referred to the “hydration effect” in DIA patches”.210 However, this 
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phenomenon also points out the detrimental effect of environmental humidity on the physical 
stability of DIA films.  
 
Figure 5.7 Inverse of experimental crystallization half time as a function of relative humidity. 
 
Figure 5.8 Adapted from Chenevas-Paule and Dodou.210 The process of water competing with the API at the H-
boinding sites of the polymer and its effect on recrystallization.e 
																																								 																				
e	Adapted	from	Development	of	a	Predictive	Model	for	the	Long-Term	Stability	Assessment	of	Drug-In-Adhesive	
Transdermal	Films	Using	Polar	Pressure-Sensitive	Adhesives	as	Carrier/Matrix,	165(3),	Chenevas-Paule	C,	Wolff	H-
M,	Ashton	M,	Schubert	M,	Dodou	K,	1293-1301.,	Copyright	(2017),	with	permission	from	Elsevier.	
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The degree of supersaturation can be used as an indicator of physical stability of DIA 
systems. Figure 5.9 shows the supersaturation of ibuprofen in Duro-Tak® 2052 at varying 
compositions and relatvie humdity under isothermal conditions. The plot was seperated into  upper 
and lower regions representing where the degree of supersaturation was lower and higher than 1, 
respectively. When the concentration of the API in the DIA system is lower than the solubility, i.e. 
S < 1, the system is considered thermodynamically stable; whereas the concentration of the API 
in the system is higher than the solubility, or S > 1, the solvated drug is unstable and tend to 
recrystallize. The type of nucleation expected relative to the value of S is commonly described by 
a solublity map.211-212 When S >> 1, homogenous nucleation is energetically permissible, and the 
supersatured solution is in the labile zone.  When S is close to 1, the system is in the metastable 
zone. Heterogeneous nulcleation and seondary nucleation are more prevalent in the metastable 
zone. At a concentration of 23.5 % w/w and a solublity of 16.17 % w/w, the degree of 
supersaturation of the DIA system is 1.45. This value of S suggests that the nucleation in the system 
is heterogeneous, which agrees with the observation that the crystallization was predominantly at 
the patch edges and interfaces.     
It can be observed from Figure 5.9 that the degree of supersaturation increased with both 
API concentartion and relative humidity. As a passive transdermal delivery sytem, the DIA system 
is typically loaded with a supersaturated amount of the API. At differnet humdity levels, the patch 
system exhibits different extent of physical stability. For example, a 18% w/w drug-adhesive film 
has a degree of supersaturation of 0.93 if it is stored at 11% RH; thus it would not recrystallze at 
this storage condition. However, a film with the same composition is more likely to crystallize if 
the hudimity increased to 56%RH since the drug concentration is higher than its solubility in the 
adhesive. This plot reiterate the importance of packaging and storing of transdermal patches.  
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Figure 5.9 Degree of supersaturation of ibuprofen as a function of relative humidity. 
 
5.4 Conclusions  
The crystallization can be described by two distinct yet inseparable processes: nucleation 
and crystal growth. The nucleation and crystal growth processes in supersaturated DIA patches are 
expected to vary with the crystallization temperature. The higher the temperature, the greater the 
thermodynamic driving force for crystallization. The crystallization rate constant is expected to 
increase exponentially with temperature within the proposed range of temperature according to the 
Arrhenius equation.  However, the solubility of the drug increases with the temperature and that 
reduces the degree of supersaturation which favors crystallization.  Water, on the other hand, 
plasticizes the solid dispersions and promote to greater molecular mobility in the system.  
In this chapter, the crystallization kinetics of iburpfen in DIA patches was determined non-
destructively by Raman spectroscopy. The predicted crystallinity was used to calculate the 
crystallization rate(1/t50) and degree of supersaturation of API in adhesive at varying humidity 
conditions.  These information were related to factors that impact the physical stability. The 
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maximum recrystallization rate was observed at a temperature above Tg and below Tm. The 
presence of water in the environment reduces the physical stability of the ibuprofen Duro-Tak® 
patches. The extent and rate of recrystallization both increased with relative humidity. 
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Chapter 6 : Summary 
	
The stability of pharmaceuticals encompasses various aspects: chemical, physical and 
microbiological. Physical stability refers to the ability of a product to maintain its physical 
dimensions and properties during the shelf-life. Physical changes are often more difficult to  
quantitate and with poor predictability compared to chemical stability.13  A sensitive and selective 
analytical tool for quantitative assessment of the drug crystallinity in pharmaceutical products 
allows for testing of different formulations and observation of the effect of those formulations on 
the recrystallization kinetics. Fundamental understanding of mechanisms of physical variations is 
essential to achieve robust formulations and must be incorporated in the drug and drug product 
developments. 
The recrystallization of a solvated drug in a DIA transdermal patch potentially hampers 
drug solubility, permeability and bioavailability. The extent of recrystallization must be closely 
monitored to reveal factors affecting crystallization. A quantitative method that is specific and 
sensitive to the crystalline form of the API facilitates the understanding of the mechanisms behind 
physical changes of pharmaceuticals. However, challenges are associated with quantification of 
solid phases in transdermal drug delivery system. The traditional solid-state quantification 
methods, which serve as reference methods, suffer from poor sensitivity. In addition, it is 
extremely difficult to achieve a homogeneous distribution of the crystalline and the solvated phases 
in the physical mixtures.  Sources of errors linked to solid-state quantification in transdermal films 
have not been reported.  
This dissertation has demonstrated the analytical capability of NIR and Raman 
spectroscopy for crystalline content quantification in a drug-in-adhesive transdermal patch system.  
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Rigorous evaluations of feasibility and performance of the analytical systems for crystalline 
content determination were conducted. The measurement setups, suitability of spiked samples, 
analytical sensitivity and selectivity, and validation strategy were included in the evaluations.  
A few practical investigations of the drug-in-adhesive systems were conducted in the early-
stage development of the spectroscopic methods. That included the characterization of the 
physicochemical properties of the DIA system and the determination of potential effects 
formulation variables had on spectra. These characteristics, including drug content and solubility 
of the API in the adhesive, are of relevance to understanding the variability of the analytical results. 
This information can also guide the initial establishment of a regression function using a suitable 
dynamic range.  
An artificial system that maximizes the spectral similarity to the naturally recrystallized 
patches were developed. The combination of two drug layers with distinct physical state 
(crystalline and solvated) makes crystallinity in each patch controllable. This method allows the 
generation of homogenous distributed crystalline particles within the patches. Recrystallization 
due to spiking was found to be insignificant in the time frame needed to complete measurements.  
With abundant information generated regarding the attributes of the spiked samples, the sample 
system prepared by coating were used for calibration.  
The assessment of the analytical capability should be conducted prior to analytical method 
development. As the assessment only uses a reduced number of samples relative to the calibration 
experiment, it is particularly useful when time and resources are limited. The analytical capabilities 
for determination of crystalline content in a DIA formulation via the NIR and Raman instruments 
were demonstrated in this dissertation. The sensitivity of an analytical tool for crystallinity 
determination cannot be thoroughly justified without comparison to a reference method. The 
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effective resolution, a quantifiable sensitivity measure, was calculated for the spiked and crystal-
free DIA patches using a backscatter Raman analyzer, a reflectance NIR spectrometer and an XRD 
diffractometer. The highest sensitivity, or the ability to detect crystalline API at the lowest 
concentration, is associated with the NIR system due to its outstanding signal to noise ratio. The 
selectivity for an analytical method was inferred from the accuracy of the predictions when 
interferences were varied. Both the Raman and the NIR preliminary models provided similar and 
accurate crystallinity predictions despite alternations of the substrate solvated drug concentrations. 
Thus, this part of the dissertation demonstrated the feasibility of the selected techniques to calibrate 
crystalline drug in spiked DIA patches.   
The importance of rigorous sample design and understanding at all levels the sample 
variability and difference between spiked and authentic samples was demonstrated in this 
dissertation. In the calibration set, the concentrations of the crystalline drug and solvated drug were 
added with minimized correlation in compositions.  This step is necessary as there is a strong 
spectral correlation between the two phases of the API. After the quantitative methods were 
established, the validity of the spiking method was carefully evaluated using two independent test 
sets. The first test set consisted of spectra of crystal-free samples, which were measured as they 
underwent recrystallization during storage. The second test set contained spectra of spiked samples 
with the same drug content to that of the first test set (their crystalline contents were varied to 
simulate the recrystallization process).  A high degree of correlation was found between the spiked 
and the recrystallized samples in terms of predicted crystallinity and their corresponding spectra.  
Method validation based on a fit-for-purpose concept was used to generate figures of merit 
for analytical methods. These figures of merit are specificity, accuracy, precision and multivariate 
detection limits (MDL). The MDL was used to set the dynamic range of the multivariate models. 
	142 
	
The traditional LOD threshold, based on 3Ÿ, is defined for univariate calibrations and it almost 
always gives an unrealistic detection limit because very few sources of errors are considered. The 
dissertation demonstrated multivariate detection limits for the NIR and the Raman methods, taking 
into accounts the uncertainties involved in all steps of the calibration and predictions. An accuracy 
profile derived from biases and intermediate precisions related the method performance to the 
predefined acceptance criteria. The b-intervals constructed from the NIR and the Raman methods 
were contained in the acceptability interval ( ±10% crystallinity) across the calibration range, 
demonstrating methods are validate for crystallinity quantification in the chosen DIA system.  
The spectroscopic methods for solid-state quantification have the potential to enhance the 
efficiency of stability studies. The fast measurement speed minimizes the risk of exposing samples 
to uncontrolled environmental conditions.   The Raman method was applied to DIA patches to 
determine the recrystallization kinetics and understand the impact of environmental factors on the 
rate of drug crystallization. The degree of supersaturation of the drug in a DIA patch increased 
with environmental humidity, reiterating the importance of packaging and storing of DIA 
transdermal patches. 
The work presented a novel approach for evaluating physical stability of transdermal drug 
products through careful calibration and validation of the analytical methods. A systematic 
approach that determines the feasibility, capability and performance of analytical methods allows 
for accurate analysis of crystalline content in recrystallized DIA systems with improved sensitivity 
and selectivity. As determination of the physical stability of solid-state pharmaceuticals remains 
to a challenge, the current methodology offers a means to understand the interplay between 
formulation factors, crystallization and drug release.  
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